Catalent (CTLT) 10-K 8 Dec 23 2023 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Jun. 30, 2023	Aug. 18, 2023	Dec. 31, 2021
Document Document And Entity Information [Abstract]
Document Type	10-K
Document Annual Report	true
Document Transition Report	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Amendment Flag	false
Document Period End Date	Jun. 30, 2023
Entity File Number	001-36587
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-8737688
Entity Address, Address Line One	14 Schoolhouse Road
Entity Address, City or Town	Somerset,
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08873
City Area Code	(732)
Local Phone Number	537-6200
Trading Symbol	CTLT
Entity Registrant Name	CATALENT, INC.
Entity Central Index Key	0001596783
Current Fiscal Year End Date	--06-30
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (shares)		180,641,272
Entity Interactive Data Current	Yes
Security Exchange Name	NYSE
Title of 12(b) Security	Common Stock, $0.01 par value per share
ICFR Auditor Attestation Flag	true
Entity Public Float			$ 7,900,000,000

Audit Information

Audit Information	12 Months Ended
	Jun. 30, 2023
Auditor [Line Items]
Auditor Name	Ernst & Young LLP
Auditor Location	Iselin, New Jersey
Auditor Firm ID	42

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Net revenue	$ 4,263,000,000	$ 4,802,000,000	$ 3,998,000,000
Cost of sales	3,223,000,000	3,188,000,000	2,646,000,000
Gross margin	1,040,000,000	1,614,000,000	1,352,000,000
Selling, general, and administrative expenses	829,000,000	844,000,000	687,000,000
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal	0	(1,000,000)	(182,000,000)
Other Cost and Expense, Operating	164,000,000	41,000,000	19,000,000
Operating earnings	(163,000,000)	730,000,000	828,000,000
Interest expense, net	186,000,000	123,000,000	110,000,000
Other (Income)/expense, net	7,000,000	(28,000,000)	(3,000,000)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	(342,000,000)	579,000,000	715,000,000
Income tax expense	(86,000,000)	80,000,000	130,000,000
Net earnings attributable to Catalent	(256,000,000)	499,000,000	585,000,000
Participating Securities, Distributed and Undistributed (Earnings) Loss, Basic	0	(16,000,000)	(56,000,000)
Net Income (Loss) Available to Common Stockholders, Basic	$ (256,000,000)	$ 483,000,000	$ 529,000,000
Earnings Per Share, Basic	$ (1.42)	$ 2.74	$ 3.15
Earnings Per Share, Diluted	$ (1.42)	$ 2.73	$ 3.11
Goodwill, Impairment Loss	$ 210,000,000	$ 0

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income / (Loss) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Net earnings	$ (256)	$ 499	$ 585
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	32	(110)	67
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax		9	0
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax		(3)	(1)
Other Comprehensive Income, Debt Securities, Derivative and Hedge, Gain (Loss), after Adjustment and Tax	(18)	27	3
Other comprehensive income /(loss), net of tax	40	(77)	69
Comprehensive income/(loss)	(216)	422	654
ACOI, Accumulated Gain (Loss), Marketable Securities
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax	4	$ (3)	$ (1)
Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax	$ (14)

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Current assets:
Cash and cash equivalents	$ 280,000,000	$ 449,000,000
Trade receivables, net	1,002,000,000	1,051,000,000
Inventories	777,000,000	702,000,000
Prepaid Expense and Other Assets, Current	633,000,000	626,000,000
Marketable Securities		89,000,000
Total current assets	2,692,000,000	2,917,000,000
Property, plant, and equipment, net	3,682,000,000	3,127,000,000
Other assets:
Goodwill	3,039,000,000	3,006,000,000
Other intangibles, net	980,000,000	1,060,000,000
Non-current deferred tax asset	55,000,000	49,000,000
Other Assets, Noncurrent	329,000,000	349,000,000
Total assets	10,777,000,000	10,508,000,000
Current liabilities:
Debt, Current	536,000,000	31,000,000
Accounts payable	424,000,000	421,000,000
Other accrued liabilities	570,000,000	646,000,000
Total current liabilities	1,530,000,000	1,098,000,000
Long-term Debt and Finance Lease Obligations	4,313,000,000	4,171,000,000
Pension liability	100,000,000	103,000,000
Non-current deferred tax liability	76,000,000	197,000,000
Other liabilities	147,000,000	164,000,000
Commitment and contingencies (see Note 14)
Total liabilities	6,166,000,000	5,733,000,000
Redeemable Preferred Stock Outstandings	$ 0	$ 0
Common Stock, Shares Authorized	1,000,000,000	1,000,000,000
Common Stock, Value, Outstanding	$ 2,000,000	$ 2,000,000
Preferred Stock, Value, Outstanding	0	0
Additional paid in capital	4,701,000,000	4,649,000,000
Accumulated deficit	262,000,000	518,000,000
Accumulated Other Comprehensive Income (Loss), Net of Tax	(354,000,000)	(394,000,000)
Total shareholders’ equity	4,611,000,000	4,775,000,000
Total liabilities, redeemable preferred stock, and shareholders’ equity	$ 10,777,000,000	$ 10,508,000,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Statement of Financial Position [Abstract]
Common stock, par value (usd per share)	$ 0.01	$ 0.01
Common Stock, Shares Authorized	1,000,000,000	1,000,000,000
Common stock, shares issued (shares)	180,000,000	179,000,000
Preferred Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized	100,000,000	100,000,000
Preferred Stock, Shares Issued & Outstanding	0	0
Temporary Equity, Par or Stated Value Per Share	$ 0.01
Temporary Equity, Shares Authorized	0
Temporary Equity, Shares Issued	0
Preferred Stock, Shares Issued	0	0
Accounts Receivable, Allowance for Credit Loss, Current	$ 46,000,000	$ 29,000,000
Temporary Equity, Shares Outstanding	0

Consolidated Statement of Chang

Consolidated Statement of Changes in Shareholder's Equity - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit	Accumulated Other Comprehensive (Loss)/Income [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Redeemable Preferred Stock Outstandings	$ 607,000,000
Common Stock, Shares, Outstanding		162,788,000
Beginning Balance at Jun. 30, 2020	2,899,000,000	$ 2,000,000	$ 3,818,000,000	$ (535,000,000)	$ (386,000,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock Issued During Period, Value, New Issues	82,000,000	$ 0	82,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		1,206,000
Stock Issued During Period, Value, Stock Options Exercised	0	$ 0
Stock Issued During Period, Value, Conversion of Convertible Securities	253,000,000		253,000,000
Equity compensation	51,000,000		51,000,000
Payments Related to Tax Withholding for Share-based Compensation	(46,000,000)
APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition	38,000,000		9,000,000
Dividends, Preferred Stock, Stock				(25,000,000)
Equity issued in lieu of cash consideration	(46,000,000)		(46,000,000)
APIC, Share-based Payment Arrangement, Other, Increase for Cost Recognition			38,000,000
Dividends, Preferred Stock	(25,000,000)			0
Net Income (Loss) Attributable to Parent	585,000,000			585,000,000
Other comprehensive income /(loss), net of tax	69,000,000				69,000,000
Ending Balance at Jun. 30, 2021	3,915,000,000	$ 2,000,000	4,205,000,000	25,000,000	(317,000,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Temporary Equity, Carrying Amount, Period Increase (Decrease)	(248,000,000)
Redeemable Preferred Stock Outstandings	359,000,000
Common Stock, Shares, Outstanding		170,549,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		935,000
Stock Issued During Period, Value, Stock Options Exercised	0	$ 0
Stock Issued During Period, Value, Conversion of Convertible Securities	362,000,000		362,000,000
Equity compensation	54,000,000		54,000,000
Payments Related to Tax Withholding for Share-based Compensation	(10,000,000)		(10,000,000)
APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition	26,000,000		26,000,000
Equity issued in lieu of cash consideration	9,000,000
APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition	12,000,000		12,000,000
Dividends, Preferred Stock	(6,000,000)			(6,000,000)
Net Income (Loss) Attributable to Parent	499,000,000			499,000,000
Other comprehensive income /(loss), net of tax	(77,000,000)				(77,000,000)
Ending Balance at Jun. 30, 2022	4,775,000,000	$ 2,000,000	4,649,000,000	518,000,000	(394,000,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Temporary Equity, Carrying Amount, Period Increase (Decrease)	(359,000,000)
Stock Issued During Period, Shares, Conversion of Convertible Securities		7,818,000
Redeemable Preferred Stock Outstandings	0
Common Stock, Shares, Outstanding		179,302,000
Stock Issued During Period, Value, New Issues		$ 1,163,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		971,000
Stock Issued During Period, Value, Stock Options Exercised	0
Equity compensation	35,000,000		35,000,000
Payments Related to Tax Withholding for Share-based Compensation	0
APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition	4,000,000
Equity issued in lieu of cash consideration	(13,000,000)
APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition			13,000,000
Net Income (Loss) Attributable to Parent	(256,000,000)			(256,000,000)
Other comprehensive income /(loss), net of tax	40,000,000				40,000,000
Ending Balance at Jun. 30, 2023	4,611,000,000	$ 2,000,000	4,701,000,000	$ 262,000,000	$ (354,000,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock Issued During Period, Shares, Conversion of Convertible Securities		5,392,000
Other Comprehensive Income, Other, Net of Tax	40,000,000
Proceeds from Tax Withholding Obligations			$ 4,000,000
Redeemable Preferred Stock Outstandings	$ 0
Common Stock, Shares, Outstanding		180,273,000

Consolidated Statement of Cha_2

Consolidated Statement of Changes in Shareholder's Equity - Shares of Common Stock	Common Stock [Member] shares
Beginning Balance - Common Stock Outstanding (shares) at Jun. 30, 2020	162,788,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	1,206,000
Ending Balance - Common Stock Outstanding (shares) at Jun. 30, 2021	170,549,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	935,000
Stock Issued During Period, Shares, Conversion of Convertible Securities	7,818,000
Ending Balance - Common Stock Outstanding (shares) at Jun. 30, 2022	179,302,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	971,000
Stock Issued During Period, Shares, Conversion of Convertible Securities	5,392,000
Ending Balance - Common Stock Outstanding (shares) at Jun. 30, 2023	180,273,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from Sale and Maturity of Marketable Securities	$ 89,000,000
Payments to Acquire Debt Securities, Available-for-sale		$ 20,000,000	$ 72,000,000
Proceeds from sale of property and equipment	8,000,000	0	0
Settlement on from sale of subsidiaries	0
Proceeds from Divestiture of Interest in Consolidated Subsidiaries		3,000,000	287,000,000
Payment for acquisitions, net of cash acquired	(474,000,000)	(1,199,000,000)	(147,000,000)
Payments to Acquire Investments	2,000,000	2,000,000	31,000,000
Segment, Expenditure, Addition to Long-Lived Assets	(576,000,000)	(660,000,000)	(686,000,000)
Net cash (used in) investing activities	(955,000,000)	(1,884,000,000)	(649,000,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from borrowing, net	715,000,000	1,100,000,000	166,000,000
Repayments of Long-term Debt	(230,000,000)	(78,000,000)	(67,000,000)
Payments of Debt Issuance Costs	(4,000,000)	(15,000,000)	(19,000,000)
Payments of Ordinary Dividends	0	4,000,000	22,000,000
Proceeds from Issuance of Common Stock	0	0	82,000,000
Proceeds from Stock Options Exercised	4,000,000	26,000,000	38,000,000
Payments Related to Tax Withholding for Share-based Compensation	0	(10,000,000)	(46,000,000)
Proceeds from (Payments for) Other Financing Activities	36,000,000	12,000,000	10,000,000
Net cash provided by/(used in) financing activities	521,000,000	1,031,000,000	142,000,000
CASH FLOWS FROM OPERATING ACTIVITIES:
Net earnings	(256,000,000)	499,000,000	585,000,000
Adjustments to reconcile earnings from continued operations to net cash from operations:
Depreciation and Amortization	422,000,000	378,000,000	289,000,000
Goodwill, Impairment Loss	210,000,000	0		$ 0
Foreign Currency Transaction Gain (Loss), before Tax	(9,000,000)	30,000,000	(4,000,000)
Amortization and write-off of debt financing costs	8,000,000	7,000,000	11,000,000
Gain (Loss) on Sale of Assets and Asset Impairment Charges	(98,000,000)	(31,000,000)	(9,000,000)
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal	0	(1,000,000)	(182,000,000)
Financing fees paid	0	4,000,000	18,000,000
Derivative, Gain (Loss) on Derivative, Net	0	(2,000,000)	(17,000,000)
Equity compensation	35,000,000	54,000,000	51,000,000
Provision/(benefit) for deferred income taxes	(127,000,000)	9,000,000	64,000,000
Provision for bad debts and inventory	143,000,000	17,000,000	41,000,000
Change in operating assets and liabilities:
(Increase)/decrease in trade receivables	53,000,000	(73,000,000)	(186,000,000)
(Increase)/decrease in inventories	(192,000,000)	(128,000,000)	(260,000,000)
Increase/(decrease) in accounts payable	(21,000,000)	37,000,000	50,000,000
Other assets/accrued liabilities, net - current and non-current	(128,000,000)	(423,000,000)	(36,000,000)
Net Cash Provided by (Used in) Operating Activities, Total	254,000,000	439,000,000	433,000,000
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations	11,000,000	(33,000,000)	17,000,000
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents	280,000,000	449,000,000	896,000,000	953,000,000
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	(169,000,000)	(447,000,000)	(57,000,000)
CASH AND EQUIVALENTS AT BEGINNING OF PERIOD	449,000,000
CASH AND EQUIVALENTS AT END OF PERIOD	280,000,000	449,000,000
SUPPLEMENTARY DISCLOSURE OF NON-CASH INVESTING ACTIVITY:
Stock Issued During Period, Value, Conversion of Convertible Securities	0	362,000,000	253,000,000
Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net				$ 47,000,000
SUPPLEMENTARY CASH FLOW INFORMATION:
Interest paid	188,000,000	116,000,000	105,000,000
Income taxes paid, net	99,000,000	53,000,000	$ 47,000,000
Capital Expenditures Incurred but Not yet Paid	18,000,000	$ 6,000,000
Restructuring Reserve, Settled without Cash	$ 18,000,000

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Business Catalent, Inc. ( “ Catalent ” or the “ Company ” ) directly and wholly owns PTS Intermediate Holdings LLC ( “PTS Intermediate ” ). PTS Intermediate directly and wholly owns Catalent Pharma Solutions, Inc. ( “ Operating Company ” ). The financial results of Catalent are primarily comprised of the financial results of Operating Company and its subsidiaries on a consolidated basis. The Company’s common stock, par value $0.01 (the “ Common Stock ” ) trades on the New York Stock Exchange under the symbol “ CTLT ” .

Revenue Recognition

Revenue Recognition	12 Months Ended
	Jun. 30, 2023
Revenue Recognition [Abstract]
Revenue from Contract with Customer	REVENUE RECOGNITION The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers . The Company generally earns its revenue by supplying goods or providing services under contracts with its customers in three primary revenue streams: manufacturing and commercial product supply, development services, and clinical supply services. The Company measures the revenue from customers based on the consideration specified in its contracts, excluding any sales incentive or amount collected on behalf of a third party, that the Company expects to be entitled to receive in exchange for transferring the promised goods to and/or performing services for the customer (the “Transaction Price”). To the extent the Transaction Price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the Transaction Price utilizing either the expected value method or the most likely amount method, depending on which method is expected to better predict the amount of consideration to which the Company will be entitled. The value of variable consideration is included in the Transaction Price if, and to the extent, it is probable that a significant reversal of the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are re-assessed each reporting period, as required, and any adjustment required is recorded on a cumulative catch-up basis, which would affect revenue and net income in the period of adjustment. The Company’s customer contracts generally include provisions entitling the Company to a termination penalty when the customer terminates prior to the contract’s nominal end date. The termination penalties in customer contracts vary but are generally considered substantive for accounting purposes and create enforceable rights and obligations throughout the stated durations of the contracts. The Company accounts for a contract termination as a contract modification in the period in which the customer gives notice of termination. The determination of the contract termination penalty is based on the terms stated in the relevant customer agreement. As of the modification date, the Company updates its estimate of the Transaction Price using the expected value method, subject to constraints, and to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are re-assessed each reporting period, as required, and any adjustment required is recorded on a cumulative catch-up basis, which would affect revenue and net income in the period of adjustment . Where multiple performance obligations exist in a single contract, the Company allocates consideration to each performance obligation using the “relative standalone selling price” as defined under ASC 606. Generally, the Company utilizes observable standalone selling prices in its allocations of consideration. If observable standalone selling prices are not available, the Company estimates the applicable standalone selling price using a cost-plus-margin approach or an adjusted market assessment approach, in each case, representing the amount that the Company believes the market is willing to pay for the applicable service. Payment is typically due 30 to 45 days following the invoice date, based on the payment terms set forth in the applicable customer agreement. The Company generally expenses sales commissions as incurred because either the amortization period is one year or less, or the balance with an amortization period greater than one year is not material. Customer contracts that include commitments by the Company to make facility space or equipment available may be deemed to include lease components, which are evaluated under ASC 842, Leases . For arrangements that contain both lease and non-lease components, consideration in the contract is allocated on a relative standalone selling-price basis. Determining the lease term and contract term of non-lease components, as well as the variable and fixed consideration in these arrangements, including when variability is resolved, often requires management judgment in order to determine the allocation to the lease and non-lease components. Manufacturing & Commercial Product Supply Revenue Manufacturing and commercial product supply revenue consists of revenue earned by manufacturing products supplied to customers under long-term commercial supply arrangements. In these arrangements, the customer typically owns and supplies the active pharmaceutical ingredient (“API”) or other proprietary materials used in the manufacturing process. The contract generally includes the terms of the manufacturing services and related product quality assurance procedures to comply with regulatory requirements. Due to the regulated nature of the Company’s business, these contract terms are highly interdependent and, therefore, are considered to be a single combined performance obligation. The transaction price is generally stated in the agreement as a fixed price per unit, with no contractual provision for a refund or price concession. In most circumstances, control is transferred to the customer over time, creating a corresponding right to recognize the related revenue, because there is no alternative use to the Company for the asset created and the Company has an enforceable right to payment for performance completed as of that date. The selection of the method for measuring progress towards the completion of the Company’s performance obligation requires judgment and is based on the nature of the products to be manufactured. For the majority of the Company’s arrangements, progress is measured based on the units of product that have successfully completed the contractually required product quality assurance process, because the conclusion of that process defines the time when the applicable contract and the related regulatory requirements permit the customer to exercise control over the product’s disposition. The customer is typically responsible for arranging the shipping and handling of product following completion of the quality assurance process. Payment is typically due 30 to 45 days after invoice date, based on the payment terms set forth in the applicable customer agreement. Beginning in the third quarter of fiscal 2023, the Company began recognizing commercial revenue for certain contracts in its Biologics segment that have a notably long manufacturing cycle, and for which the customer exercises control over the product throughout the manufacturing process. For these contracts, revenue is recognized over time and progress is measured using an input method based on effort expended, which provides an appropriate depiction of the Company’s progress toward fulfilling its performance obligation. Development Services and Clinical Supply Revenue Development services contracts generally take the form of short-term, fee-for-service arrangements. Performance obligations vary, but frequently include biologic cell-line development, performing formulation, analytical stability, or other services related to product development, and providing manufacturing services for products that are under development or otherwise not intended for commercial sale. They can also include a combination of the following services: the manufacturing, packaging, storage, distribution, destruction, and inventory management of customer clinical trial material, as well as the sourcing of comparator drug products on behalf of customers to be used in clinical trials to compare performance with the drug under clinical investigation. The transaction prices for these arrangements are fixed and include amounts stated in the contracts for each promised service, and each service is generally considered to be a separate performance obligation. In most instances, the Company recognizes revenue over time because there is no alternative use to the Company for the asset created and the Company has an enforceable right to payment for performance completed as of that date. The Company measures progress toward the completion of its performance obligations satisfied over time based on the nature of the services to be performed. For certain types of arrangements, revenue is recognized over time and measured using an output method based on the completion of tasks and activities that are performed to satisfy a performance obligation. For certain types of arrangements, revenue is recognized over time and measured using an input method based on effort expended. Each of these methods provides an appropriate depiction of the Company’s progress toward fulfilling its performance obligations for its respective arrangement. In certain development services arrangements that require a portion of the contract consideration to be received in advance at the commencement of the contract, such advance payment is initially recorded as a contract liability. In certain clinical supply arrangements, revenue is recognized at the point in time when control transfers, which occurs upon either the delivery of the related output of the service to the customer or the completion of quality testing with respect to the product, and the Company has an enforceable right to payment based on the terms of the arrangement. The Company records revenue for comparator sourcing arrangements on a net basis because it is acting as an agent that does not control the product or service before it is transferred to the customer. Payment for comparator sourcing activity is typically received in advance at the commencement of the contract and is initially recorded as a contract liability. The Company generally expenses sales commissions as incurred because either the amortization period is one year or less, or the balance with an amortization period greater than one year is not material. The following tables reflect net revenue for the fiscal years ended June 30, 2023, 2022, and 2021 by type of activity and reporting segment (in millions): Fiscal Year Ended June 30, 2023 Biologics Pharma and Consumer Health Total Manufacturing & commercial product supply $ 450 $ 1,452 $ 1,902 Development services & clinical supply 1,528 835 2,363 Total $ 1,978 $ 2,287 $ 4,265 Inter-segment revenue elimination (2) Combined net revenue $ 4,263 Fiscal Year Ended June 30, 2022 Biologics Pharma and Consumer Health Total Manufacturing & commercial product supply $ 608 $ 1,474 $ 2,082 Development services & clinical supply 1,926 797 2,723 Total $ 2,534 $ 2,271 $ 4,805 Inter-segment revenue elimination (3) Combined net revenue $ 4,802 Fiscal Year Ended June 30, 2021 Biologics Pharma and Consumer Health Total Manufacturing & commercial product supply $ 532 $ 1,321 $ 1,853 Development services & clinical supply 1,406 742 2,148 Total $ 1,938 $ 2,063 $ 4,001 Inter-segment revenue elimination (3) Combined net revenue $ 3,998 The following table reflects net revenue by the location where the goods were made or the service performed: (Dollars in millions) Fiscal Year Ended Fiscal Year Ended Fiscal Year Ended United States $ 2,768 $ 3,084 $ 2,462 Europe 1,257 1,506 1,343 Other 355 327 288 Elimination of revenue attributable to multiple locations (117) (115) (95) Total $ 4,263 $ 4,802 $ 3,998 Contract Liabilities Contract liabilities relate to cash consideration that the Company receives in advance of satisfying the related performance obligations. The contract liabilities balances (current and non-current) as of June 30, 2023 and June 30, 2022 were as follows: (Dollars in millions) Balance at June 30, 2022 $ 220 Balance at June 30, 2023 $ 180 Revenue recognized in the period from amounts included in contracts liability at the beginning of the period: $ 126 Contract liabilities that will be recognized within 12 months of June 30, 2023 are accounted for in Other accrued liabilities and those that will be recognized longer than 12 months after June 30, 2023 are accounted for within Other liabilities. Contract Assets Contract assets primarily relate to the Company's conditional right to receive consideration for services that have been performed for customers but had not yet been invoiced as of June 30, 2023. Contract assets are transferred to trade receivables, net when the Company’s right to receive the consideration becomes unconditional. Contract assets totaled $417 million and $441 million as of June 30, 2023 and 2022, respectively. Contract assets expected to transfer to trade receivables within 12 months are accounted for within Prepaid expenses and other. Contract assets expected to transfer to trade receivables after 12 months are accounted for within Other long-term assets. As of June 30, 2023, the Company recorded no reserve against any of its contract asset balances. Performance Obligations Remaining performance obligations represent firm orders for future development services as well as manufacturing and commercial product supply, including minimum volume commitments, for which there are incomplete performance obligations for work not yet completed under executed contracts. Remaining performance obligations as of June 30, 2023 were $335 million. The Company expects to recognize approximately 42% of the remaining performance obligations in existence as of June 30, 2023 after June 30, 2024.

Goodwill

Goodwill	12 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	GOODWILL The following table summarizes the changes from June 30, 2021 to June 30, 2022 and then to June 30, 2023 in the carrying amount of goodwill in total and by reportable segment: (Dollars in millions) Biologics Pharma and Consumer Health Total Balance at June 30, 2021 $ 1,562 $ 957 $ 2,519 Additions (1) 41 531 572 Foreign currency translation adjustments (37) (48) (85) Balance at June 30, 2022 1,566 1,440 3,006 Additions (2) — 219 219 Reallocation (15) 15 — Foreign currency translation adjustments 12 12 24 Impairment (3) — (210) (210) Balance at June 30, 2023 $ 1,563 $ 1,476 $ 3,039 (1) The additions to goodwill arise from the Bettera Wellness (Pharma and Consumer Health), Princeton (Biologics), RheinCell (Biologics), and Delphi (Biologics) acquisitions. For further details, see Note 3, Business Combinations and Divestitures . (2) The addition to goodwill is a result of the Metrics acquisition. For further details, see Note 3, Business Combinations and Divestitures . (3) Represents gross and accumulated impairment charges. As part of the business reorganization discussed in Note 1, Basis of Presentation and Summary of Significant Accounting Policies , the goodwill from the previous Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services segments was reallocated between the current Biologics and Pharma and Consumer Health segments.

Definite Lived Long-Lived Asset

Definite Lived Long-Lived Assets	12 Months Ended
	Jun. 30, 2023
Finite lived intangible assets disclosure [Abstract]
Definite Lived Long-Lived Assets	OTHER INTANGIBLES, NET The details of other intangible assets subject to amortization as of June 30, 2023 and June 30, 2022 are as follows (in millions): June 30, 2023 Weighted Average Life Gross Carrying Value Accumulated Amortization Net Carrying Value Amortized intangibles: Core technology 11 years $ 482 $ (164) $ 318 Customer relationships 13 years 1,079 (451) 628 Product relationships 8 years 243 (216) 27 Other 5 years 24 (17) 7 Total other intangibles $ 1,828 $ (848) $ 980 June 30, 2022 Weighted Average Life Gross Carrying Value Accumulated Amortization Net Carrying Value Amortized intangibles: Core technology 11 years $ 480 $ (121) $ 359 Customer relationships 13 years 1,020 (366) 654 Product relationships 8 years 239 (204) 35 Other 4 years 24 (12) 12 Total other intangibles $ 1,763 $ (703) $ 1,060 Amortization expense was $136 million, $123 million, and $93 million for the fiscal years ended June 30, 2023, 2022, and 2021, respectively. Future amortization expense is estimated to be: (Dollars in millions) 2024 2025 2026 2027 2028 Thereafter Total Amortization $ 137 $ 134 $ 126 $ 109 $ 101 $ 373 $ 980

Restructuring and Other Costs

Restructuring and Other Costs	12 Months Ended
	Jun. 30, 2023
Restructuring and Related Activities [Abstract]
Restructuring and Other Costs	RESTRUCTURING COSTS From time to time, the Company implements plans to restructure certain operations, both domestically and internationally. The restructuring plans focus on various aspects of operations, including, among others, closing and consolidating certain manufacturing operations, rationalizing headcount and aligning operations in a strategic and more cost-efficient structure. In addition, the Company may incur restructuring charges in the future in cases where a material change in the scope of operation with its business occurs. Employee-related restructuring costs consist primarily of severance costs and also include outplacement services provided to employees who have been involuntarily terminated and duplicate payroll costs during transition periods. Facility exit and other such restructuring costs consist of equipment relocation costs and costs associated with planned facility expansions and closures to streamline Company operations. During the three months ended December 31, 2022, the Company adopted plans to reduce costs, consolidate facilities, and optimize its infrastructure across the organization. During the three months ended June 30, 2023, the Company expanded its restructuring efforts by adopting an incremental plan to reduce costs and headcount, primarily in its Biologics segment and corporate functions. In connection with these restructuring plans, the Company reduced its headcount by approximately 1,100 employees and incurred cumulative employee-related charges of $ 38 Restructuring costs for the fiscal years ended June 30, 2023, 2022, and 2021 were recorded in Other operating (income) expense in the consolidated statement of operations. The following tables summarize the restructuring costs by type of cost and reportable segment: Fiscal Year Ended June 30, (Dollars in millions) 2023 2022 2021 Restructuring costs: Employee-related reorganization $ 38 $ 9 $ 8 Facility exit and other costs 28 1 2 Total restructuring costs $ 66 $ 10 $ 10 Fiscal Year Ended June 30, (Dollars in millions) 2023 2022 2021 Restructuring costs: Biologics $ 41 $ 1 $ — Pharma and Consumer Health 8 5 9 Non-segment (Corporate) 17 4 1 Total restructuring costs $ 66 $ 10 $ 10 The following tables illustrates the change in the employee separation-related liability associated with the plans.
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]	Selling, general, and administrative expenses

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	12 Months Ended
	Jun. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities	DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES Risk Management Objective of Using Derivatives The Company is exposed to fluctuations in the currency exchange rates applicable to its investments in foreign operations. While the Company does not actively hedge against changes in foreign currency, the Company has mitigated the exposure arising from its investments in its European operations by denominating a portion of its Senior Notes in euros. At June 30, 2023, the Company had euro-denominated debt outstanding of $904 million (U.S. dollar equivalent), which qualifies as a hedge of a net investment in foreign operations. For non-derivatives designated and qualifying as net investment hedges, the effective portion of the translation gains or losses are reported in accumulated other comprehensive income (loss) as part of the cumulative translation adjustment. The unhedged portions of the translation gains or losses are reported in the consolidated statements of operations. The following table includes net investment hedge activity during the fiscal years ended June 30, 2023 and 2022, respectively: (Dollars in millions) June 30, 2023 June 30, 2022 Unrealized foreign exchange gain (loss) within other comprehensive income $ (30) $ 121 Unrealized foreign exchange loss within statement of operations $ — $ (11) The net accumulated gain of this net investment hedge within accumulated other comprehensive loss was $97 million as of June 30, 2023. Amounts are reclassified out of accumulated other comprehensive loss into earnings when the entity in which the gains and losses reside is either sold or substantially liquidated. Interest-Rate Swap In April 2020, pursuant to its interest rate and risk management strategy, the Company entered into an interest-rate swap agreement with Bank of America N.A. (the “2020 Rate Swap”) as a hedge against the economic effect of a portion of the variable interest obligation associated with its U.S. dollar-denominated term loans under its senior secured credit facilities. In February 2021, in connection with an amendment to the Credit Agreement, the Company paid $2 million in cash to Bank of America N.A to settle the 2020 Rate Swap. This loss is deferred in stockholders’ equity, net of income taxes, as a component of accumulated other comprehensive loss, and amortized as an adjustment to interest expense, net over the original term of the formerly outstanding term loans. The net amount of deferred losses on cash flow hedges that is expected to be reclassified from accumulated other comprehensive loss into interest expense, net within the next twelve months is not material. In February 2021, the Company entered into a new interest-rate swap agreement with Bank of America N.A. (the “2021 Rate Swap”) that acted as a hedge against the economic effect of a portion of the variable-interest obligation associated with the Company's U.S. dollar-denominated term loans under its senior secured credit facilities. The 2021 Rate Swap effectively fixed the rate of interest payable on that portion of the term loans, thereby reducing the impact of future interest rate changes on future interest expense. As a result of the 2021 Rate Swap, the variable portion of the applicable interest rate on $500 million of the U.S. dollar-denominated term loans was effectively fixed at 0.9985%. To conform with the adoption of Topic 848, Reference Rate Reform and the Eighth Amendment , the Company amended the 2021 Rate Swap in June 2023 (the “2023 Rate Swap”). The 2023 Rate Swap continues to effectively fix the rate of interest payable on the same portion of our U.S. dollar-denominated term loans under our senior secured credit facilities. As a result of the 2023 Rate Swap, the variable portion of the applicable interest rate on $500 million of the U.S. dollar-denominated term loans is now effectively fixed at 0.9431%. The 2023 Rate Swap continues to qualify for a cash-flow hedge. The Company evaluates hedge effectiveness at the inception of the hedge and on an ongoing basis. The cash flows associated with the 2023 Rate Swap amendment is reported in cash provided by operating activities in the consolidated statements of cash flows. The unrealized gain recorded in stockholder's equity from marking the 2021 Rate Swap to market during the fiscal year ended June 30, 2023 was $25 million. A summary of the estimated fair value of the interest-rate swap reported in the consolidated balance sheets is stated in the table below: June 30, 2023 June 30, 2022 (in millions) Balance Sheet Classification Estimated Fair Value Balance Sheet Classification Estimated Fair Value Interest-rate swap Other long-term assets $ 62 Other long-term assets $ 36

Fair Value Measures and Disclos

Fair Value Measures and Disclosures	12 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Disclosures	FAIR VALUE MEASUREMENTS ASC 820, Fair Value Measurement defines fair value as the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs and minimize the use of unobservable inputs. To measure fair value, the Company uses the following fair value hierarchy based on three levels of inputs, of which Level 1 and Level 2 are considered observable and Level 3 is considered unobservable: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and also includes instruments for which the determination of fair value requires significant judgment or estimation. Assets and Liabilities Measured at Fair Value on a Recurring Basis The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses of the Company approximate fair value based on the short maturities of these instruments. The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level of classification as of the end of each reporting period. The following table sets forth the Company’s financial assets and liabilities that were measured at fair value on a recurring basis and the fair value measurement for such assets and liabilities at June 30, 2023 and 2022, respectively: (Dollars in millions) Basis of Fair Value Measurement June 30, 2023 Total Level 1 Level 2 Level 3 Assets: Interest-rate swap $ 62 $ — $ 62 $ — Trading securities $ 1 $ 1 $ — $ — June 30, 2022 Assets: Marketable securities $ 89 $ 89 $ — $ — Interest-rate swap 36 — 36 — Trading securities $ 2 $ 2 $ — $ — The fair value of the 2021 Rate Swap was determined, and the fair value of the 2023 Rate Swap will be determined, at the end of each reporting period based on valuation models that use interest rate yield curves and discount rates as inputs. The discount rates are based on U.S. deposit or U.S. Treasury rates. The significant inputs used in the valuation models are readily available in public markets or can be derived from observable market transactions, and the valuation is therefore classified as Level 2 in the fair-value hierarchy. Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis Long-lived assets, goodwill, and other intangible assets are subject to non-recurring fair value measurement for the evaluation of potential impairment. The carrying value of the Consumer Health reporting unit approximates its fair value as of June 30, 2023 following the impairment charge. Other than the valuation of the Consumer Health reporting unit, there was no non-recurring fair value measurement during the fiscal years ended June 30, 2023 and 2022.

Employee Retirement Benefit Pla

Employee Retirement Benefit Plans	12 Months Ended
	Jun. 30, 2023
Retirement Benefits [Abstract]
Employee Retirement Benefit Plans	EMPLOYEE RETIREMENT BENEFIT PLANS The Company sponsors various retirement plans, including defined benefit pension plans and defined contribution plans. Substantially all of the Company’s domestic non-union employees are eligible to participate in employer-sponsored retirement savings plans, which include plans created under Section 401(k) of the Internal Revenue Code that provide for the Company to match a portion of contributions by participating U.S. employees. The Company’s contributions to the plans are discretionary but are subject to certain minimum requirements as specified in the plans. The Company uses a measurement date of June 30 for all of its retirement and postretirement benefit plans. The Company records obligations related to its withdrawal from one multi-employer pension plan that covered former employees at three former sites. This withdrawal was classified as a mass withdrawal under the Multiemployer Pension Plan Amendments Act of 1980, as amended, and the Pension Protection Act of 2006 and resulted in the recognition of liabilities associated with the Company’s long-term obligations in prior years not presented, which were primarily recorded as an expense within discontinued operations. The estimated discounted value of the projected contributions related to these plans is $38 million as of June 30, 2023 and 2022. The annual cash impact associated with the Company’s long-term obligation arising from this plan is $2 million per year. The following table provides a reconciliation of the change in projected benefit obligation and fair value of plan assets for the defined benefit retirement and other retirement plans, excluding the multi-employer pension plan liability: Retirement Benefits Other Post-Retirement Benefits June 30, June 30, (Dollars in millions) 2023 2022 2023 2022 Accumulated Benefit Obligation $ 242 $ 262 $ 2 $ 2 Change in Benefit Obligation Benefit obligation at beginning of year 268 372 2 2 Company service cost 3 4 — — Interest cost 9 5 — — Employee contributions 1 — — — Settlements (4) (1) — — Benefits paid (10) (9) — — Actuarial gain (1) (28) (71) — — Exchange rate gain (loss) 7 (32) — — Benefit obligation at end of year $ 246 $ 268 $ 2 $ 2 Change in Plan Assets Fair value of plan assets at beginning of year 240 318 — — Actual return on plan assets (38) (50) — — Company contributions 7 10 — — Employee contributions 1 — — — Settlements (4) (1) — — Benefits paid (10) (9) — — Exchange rate gain (loss) 6 (28) — — Fair value of plan assets at end of year $ 202 $ 240 $ — $ — Funded Status Funded status at end of year (44) (28) (2) (2) Net pension liability $ (44) $ (28) $ (2) $ (2) (1) For the fiscal year ended June 30, 2022, the actuarial gain is driven by a large increase in the aggregate discount rate. The following table provides a reconciliation of the net amount recognized in the consolidated balance sheets: Retirement Benefits Other Post-Retirement Benefits June 30, June 30, (Dollars in millions) 2023 2022 2023 2022 Amounts Recognized in Statement of Financial Position Noncurrent assets $ 18 $ 37 $ — $ — Current liabilities (1) (1) — — Noncurrent liabilities (61) (64) (2) (2) Total liability (44) (28) (2) (2) Amounts Recognized in Accumulated Other Comprehensive Loss Prior service cost (1) (1) — — Net loss (gain) 66 49 (1) (1) Total accumulated other comprehensive loss (income) at the end of the fiscal year 65 48 (1) (1) Additional Information for Plan with ABO or PBO in Excess of Plan Assets Projected benefit obligation 129 132 2 2 Accumulated benefit obligation 126 128 2 2 Fair value of plan assets 68 67 — — Components of Net Periodic Benefit Cost Service cost 3 4 — — Interest cost 9 5 — — Expected return on plan assets (9) (10) — — Amortization of unrecognized: Net loss 1 2 — — Settlement/curtailment expense 1 — — — Net periodic benefit cost $ 5 $ 1 $ — $ — Retirement Benefits Other Post-Retirement Benefits June 30, June 30, (Dollars in millions) 2023 2022 2023 2022 Other Changes in Plan Assets and Benefit Obligations Recognized in Other Comprehensive Income Net loss (gain) arising during the year $ 17 $ (14) $ — $ — Exchange rate loss recognized during the year — 1 — — Total recognized in other comprehensive income $ 17 $ (13) $ — $ — Total Recognized in Net Periodic Benefit Cost and Other Comprehensive Income Total recognized in net periodic benefit cost and other comprehensive income $ 22 $ (12) $ — $ — Estimated Amounts to be Amortized from Accumulated Other Comprehensive Income into Net Periodic Benefit Cost Amortization of: Net loss $ 2 $ 1 $ — $ — Financial Assumptions Used to Determine Benefit Obligations at the Balance Sheet Date Discount rate (%) 4.3 % 3.6 % 4.7 % 4.0 % Rate of compensation increases (%) 2.7 % 2.7 % n/a n/a Financial Assumptions Used to Determine Net Periodic Benefit Cost for Financial Year Discount rate (%) 3.6 % 1.6 % 4.0 % 2.0 % Rate of compensation increases (%) 2.7 % 2.0 % n/a n/a Expected long-term rate of return (%) 3.9 % 3.4 % n/a n/a Expected Future Contributions Fiscal year 2024 $ 8 $ 7 $ — $ — Retirement Benefits Other Post-Retirement Benefits June 30, June 30, (Dollars in millions) 2023 2022 2023 2022 Expected Future Benefit Payments Financial year 2024 $ 14 $ 14 $ — $ — 2025 15 13 — — 2026 16 14 — — 2027 15 16 — — 2028 15 14 — — 2029-2033 84 80 1 1 Actual Asset Allocation (%) Cash 4.5 % — % — % — % Equities 2.9 % 4.1 % — % — % Government bonds 36.8 % 35.6 % — % — % Corporate bonds 16.2 % 18.3 % — % — % Property 3.3 % 4.9 % — % — % Insurance contracts 14.9 % 12.0 % — % — % Other 21.4 % 25.1 % — % — % Total 100.0 % 100.0 % — % — % Actual Asset Allocation (Amount) Cash $ 9 $ — $ — $ — Equities 6 10 — — Government bonds 74 85 — — Corporate bonds 33 44 — — Property 7 12 — — Insurance contracts 30 29 — — Other 43 60 — — Total $ 202 $ 240 $ — $ — Target Asset Allocation (%) Cash 4.5 % — % — % — % Equities 2.9 % 4.1 % — % — % Government bonds 36.8 % 35.6 % — % — % Corporate bonds 16.2 % 18.3 % — % — % Property 3.3 % 4.9 % — % — % Insurance contracts 14.9 % 12.0 % — % — % Other 21.4 % 25.1 % — % — % Total 100.0 % 100.0 % — % — % The Company's Investment Committee employs a building-block approach in determining the long-term rate of return for plan assets, with proper consideration of diversification and rebalancing. Historical markets are studied and long-term historical relationships between equities and fixed income are preserved consistent with the widely accepted capital market principle that assets with higher volatility generate a greater return over the long run. Current market factors such as inflation and interest rates are evaluated before long-term capital market assumptions are determined. Peer data are reviewed to check for reasonability and appropriateness. Plan assets are recognized and measured at fair value in accordance with the accounting standards regarding fair value measurements. The following are valuation techniques used to determine the fair value of each major category of assets: • Short-term investments, equity securities, fixed-income securities, and real estate are valued using quoted market prices or other valuation methods, and thus are classified within Level 1 or Level 2. • Insurance contracts and other types of investments include investments with some observable and unobservable prices that are adjusted by cash contributions and distributions, and thus are classified within Level 2 or Level 3. The following tables provide a summary of plan assets that are measured at fair value as of June 30, 2023 and 2022, aggregated by the level in the fair value hierarchy within which those measurements fall: As of June 30, 2023 (dollars in millions) Level 1 Level 2 Level 3 Investments Measured at Net Asset Value Total Assets Equity securities $ — $ 6 $ — $ — $ 6 Debt securities — 107 — — 107 Real estate — 5 2 — 7 Other (1) — 57 25 — 82 Total $ — $ 175 $ 27 $ — $ 202 (1) Other, as of June 30, 2023, included $20 million of investments in hedge funds related to the Company's U.K. pension plan, which were classified as Level 2. As of June 30, 2022 (dollars in millions) Level 1 Level 2 Level 3 Investments Measured at Net Asset Value Total Assets Equity securities $ — $ 10 $ — $ — $ 10 Debt securities — 129 — — 129 Real estate — 10 2 — 12 Other (1) — 64 25 — 89 Total $ — $ 213 $ 27 $ — $ 240 (1) Other, as of June 30, 2022, included $35 million of investments in hedge funds related to the Company's U.K. pension plan, which were classified as Level 2. Level 3 other assets as of June 30, 2023 and 2022 consist of an insurance contract in the U.K. to fulfill the benefit obligations for a portion of the participant benefits. The value of this commitment is determined using the same assumptions and methods used to value the pension liability of the associated plan. Level 3 other assets for the same periods also include the partial funding of a pension liability relating to current and former employees of the Company’s Eberbach, Germany facility through a Company promissory note with an annual rate of interest of 5%. The value of this commitment fluctuates due to contributions and benefit payments in addition to loan interest. The following table provides a reconciliation of the beginning and ending balances of Level 3 assets as well as the changes during the period attributable to assets held and those purchases, sales, settlements, contributions, and benefits that were paid: Fair Value Measurement Using Significant Unobservable Inputs Total (Level 3) Fair Value Measurement Using Significant Unobservable Inputs Insurance Contracts Fair Value Measurement Using Significant Unobservable Inputs Other Total (Level 3) (Dollars in millions) Beginning Balance at June 30, 2022 $ 27 $ 9 $ 18 Actual return on plan assets: Relating to assets still held at the reporting date 2 — 2 Purchases, sales, settlements, contributions and benefits paid (3) (1) (2) Transfers in or out of Level 3, net 1 — 1 Ending Balance at June 30, 2023 $ 27 $ 8 $ 19 The Company's investment policy reflects the long-term nature of the plans’ funding obligations. The assets are invested to provide the opportunity for both income and growth of principal. This objective is pursued as a long-term goal designed to provide required benefits for participants without undue risk. It is expected that this objective can be achieved through a well-diversified asset portfolio. All equity investments are made within the guidelines of quality, marketability, and diversification mandated by the Employee Retirement Income Security Act of 1974, as amended (for plans subject to the act) and other relevant legal requirements. Investment managers are directed to maintain equity portfolios at a risk level approximately equivalent to that of the specific benchmark established for that portfolio. Assets invested in fixed income securities and pooled fixed-income portfolios are managed actively to pursue opportunities presented by changes in interest rates, credit ratings, or maturity premiums. Other Post-Retirement Benefits Assumed Healthcare Cost Trend Rates at the Balance Sheet Date 2023 2022 Healthcare cost trend rate – initial (%) Pre-65 n/a n/a Post-65 4.8 % 4.6 % Healthcare cost trend rate – ultimate (%) Pre-65 n/a n/a Post-65 4.1 % 4.1 % Year in which ultimate rates are reached Pre-65 n/a n/a Post-65 2040 2040

Other Income _ Expense

Other Income / Expense	12 Months Ended
	Jun. 30, 2022
Other Income and Expenses [Abstract]
Other Income and Other Expense Disclosure	OTHER (INCOME) EXPENSE, NET The components of other expense, net for the fiscal years ended June 30, 2023, 2022, and 2021 are as follows: Fiscal Year Ended (Dollars in millions) 2023 2022 2021 Other (income) expense, net Debt refinancing costs (1) $ — $ 4 $ 18 Foreign currency (gains) losses (2) (8) 33 5 Other (3) 1 (9) (20) Total other (income) expense, net $ (7) $ 28 $ 3 (1) Debt financing costs for the fiscal year ended June 30, 2022 consists of $4 million of financing charges related to a tranche of U.S. dollar-denominated term loans under its senior secured credit facilities. Debt financing costs for the fiscal year ended June 30, 2021 includes (a) a write-off of $4 million of previously capitalized financing charges related to the Company’s repayment of U.S. dollar-denominated term loans and the 2026 Notes in February 2021, (b) $3 million of financing charges related to the issuance of an earlier tranche of the Company's U.S dollar-denominated term loans, and (c) an $11 million premium on early redemption of the 2026 Notes. (2) Foreign currency losses (gains) include both cash and non-cash transactions.

Leases

Leases	12 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Lessee, Finance Leases	LEASES The Company leases certain manufacturing and office facilities, land, vehicles, and equipment. The terms of these leases vary widely, although most have terms between 3 and 10 years. In accordance with ASC 842 , Leases , the Company recognizes a “right-of-use” asset and related lease liability at the commencement date of each lease based on the present value of the fixed lease payments over the expected lease term inclusive of any rent escalation provisions or incentives received. The lease term for this purpose will include any renewal period where the Company determines that it is reasonably certain that it will exercise the option to renew. While certain leases also permit the Company to terminate the lease in advance of the nominal term upon payment of an associated penalty, the Company generally does not take into account potential early termination dates in its determination of the lease term as it is reasonably certain not to exercise an early-termination option as of the lease commencement date. The Company uses its incremental borrowing rate, which represents the interest rate the Company would expect to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms, in order to calculate the present value of a lease, when the implicit discount rate for its leases is not readily determinable. For operating leases, fixed lease payments are recognized as operating lease expense on straight-line basis over the lease term. For finance leases, the Company recognizes depreciation expense associated with the leased asset acquired and interest expense related to the financing portion. Variable payments are recognized in the period incurred. As permitted by ASC 842, the Company has elected not to separate those components of a lease agreement not related to the leasing of an asset from those components that are related. The Company does not record leases with an initial lease term of 12 months or less on its consolidated balance sheets. The Company recognizes lease expense for these short-term leases on a straight-line basis over the lease term. Supplemental information concerning the leases recorded in the Company's consolidated balance sheet as of June 30, 2023 is detailed in the following table: (Dollars in millions) Line item in the consolidated balance sheet Balance at Right-of-use assets: Finance leases Property, plant, and equipment, net $ 274 Operating leases Other long-term assets 59 Current lease liabilities: Finance leases Current portion of long-term obligations and other short-term borrowings 18 Operating leases Other accrued liabilities 11 Non-current lease liabilities: Finance leases Long-term obligations, less current portion 323 Operating leases Other liabilities $ 55 The components of the net lease costs for the fiscal year ended June 30, 2023 reflected in the Company's consolidated statement of operations were as follows: (Dollars in millions) Fiscal Year Ended Financing lease costs: Amortization of right-of-use assets $ 21 Interest on lease liabilities 17 Total 38 Operating lease costs 35 Variable lease costs 10 Total lease costs $ 83 The short-term lease cost amounted to $10 million during the fiscal year ended June 30, 2023. The weighted average remaining lease term and weighted average discount rate related to the Company's right-of-use assets and lease liabilities as of June 30, 2023 are as follows: Weighted average remaining lease term (years): Finance leases 17.4 Operating leases 10.7 Weighted average discount rate: Finance leases 6.4 % Operating leases 4.3 % Supplemental information concerning the cash-flow impact arising from the Company's leases for the fiscal year ended June 30, 2023 recorded in the Company's unaudited consolidated statement of cash flows is detailed in the following table (in millions): Fiscal Year Ended Cash paid for amounts included in lease liabilities: Financing cash flows used for finance leases $ 19 Operating cash flows used for finance leases 15 Operating cash flows used for operating leases 16 Non-cash transactions: Right-of-use assets obtained in exchange for new finance lease liabilities 133 Right-of-use assets obtained in exchange for new operating lease liabilities $ 1 As of June 30, 2023, the Company expects that its future minimum lease payments will become due and payable as follows: (Dollars in millions) Financing Leases Operating Leases Total 2024 $ 35 $ 13 $ 48 2025 34 10 44 2026 35 9 44 2027 35 9 44 2028 33 7 40 Thereafter 380 38 418 Total minimum lease payments 552 86 638 Less: interest 211 20 231 Total lease liabilities $ 341 $ 66 $ 407

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES Litigation From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business, including, without limitation, inquiries and claims concerning environmental contamination as well as litigation and allegations in connection with acquisitions, product liability, manufacturing or packaging defects, and claims for reimbursement for the cost of lost or damaged active pharmaceutical ingredients, the cost of any of which could be significant. Such matters are inherently uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will not have a material adverse effect upon the Company’s consolidated financial statements. The Company records a liability in its consolidated financial statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated. The Company reviews these estimates each accounting period as additional information is known and adjusts the loss provision when appropriate. If a matter is both probable to result in a liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible loss or range of loss to the extent necessary for its consolidated financial statements not to be misleading. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in the Company's consolidated financial statements. Any legal or other expenses associated with the litigation are accrued for as the expenses are incurred. The Company intends to vigorously defend itself against any such litigation and does not currently believe that the outcome of any such litigation will have a material adverse effect on the Company’s consolidated financial statements. In addition, the healthcare industry is highly regulated and government agencies continue to scrutinize certain practices affecting government programs and otherwise. City of Warwick Retirement System Class Action In February 2023, an alleged shareholder filed a complaint styled City of Warwick Retirement System v. Catalent, Inc., et al ., No. 23-cv-01108, in New Jersey federal court against the Company and three of its then-officers (collectively, “the Warwick Defendants”) purportedly on behalf of a putative “class” consisting of persons who purchased or otherwise acquired Company securities between August 30, 2021 and October 31, 2022, inclusive. On September 15, 2023, the Warwick complaint was amended (together with the original complaint, the “ Warwick Complaint”), which amended complaint expanded the class period to between August 30, 2021 and May 7, 2023, inclusive (the “Class Period”). The Complaint purports to assert claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended and the related regulations, alleging that, unbeknownst to investors, the Warwick Defendants purportedly engaged in accounting and channel stuffing schemes to pad Catalent’s revenues and failed to disclose adverse facts that purportedly were known to or recklessly disregarded by the Warwick Defendants. Specifically, the Warwick Complaint alleges that the Warwick Defendants (i) overstated revenue and earnings by prematurely recognizing revenue in violation of U.S. GAAP; (ii) suffered material weaknesses in its internal control over financial reporting related to revenue recognition; (iii) falsely represented demand for its products while knowingly selling more product to its direct customers than could be sold to healthcare providers and end consumers; (iv) cut corners on safety and control procedures at key production facilities; (v) disregarded regulatory rules at key production facilities in order to rapidly produce excess inventory that was used to pad the Company’s financial results through premature revenue recognition in violation of U.S. GAAP or stuffing its direct customers with this excess inventory; and (vi) lacked a reasonable basis for their positive statements about the Company’s financial performance, outlook, and regulatory compliance during the Class Period. The Company believes that the Warwick Defendants have defenses to the allegations and claims set forth in the complaint and filed a motion to dismiss the Warwick Complaint on November 15, 2023. Subpoenas and Requests for Information From time to time, the Company receives subpoenas or requests for information from various governmental agencies or private parties, including from state attorneys general, the U.S. Department of Justice, and private parties. The Company generally responds to such subpoenas and requests in a timely and thorough manner, which responses sometimes require considerable time and effort and can result in considerable costs being incurred. In June 2023, the Company received a demand from a company stockholder pursuant to 8 Del. C. § 220 to inspect books and records of the Company relating to, among other things, the allegations raised in the Warwick Complaint. The Company has responded to the demand and cannot determine at this time if the books and records demand will lead to litigation.

Segment Information

Segment Information	12 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	SEGMENT AND GEOGRAPHIC INFORMATION The Company evaluates the performance of its segments based on segment earnings before other (income) expense, impairments, restructuring costs, interest expense, income tax expense, and depreciation and amortization ( “ Segment EBITDA ” ). Segment EBITDA is subject to important limitations. These consolidated financial statements include information concerning Segment EBITDA (a) because Segment EBITDA is an operational measure used by management in the assessment of the operating segments, the allocation of resources to the segments, and the setting of strategic goals and annual goals for the segments, and (b) in order to provide supplemental information that the Company considers relevant for the readers of the consolidated financial statements. The Company’s presentation of Segment EBITDA may not be comparable to similarly titled measures used by other companies. The following table includes Segment EBITDA for each of the Company's current reporting segments during the fiscal years ended June 30, 2023, 2022, and 2021: (Dollars in millions) Fiscal Year Ended June 30, 2023 2022 2021 Segment EBITDA reconciled to net (loss) earnings: Biologics $ 277 $ 777 $ 615 Pharma and Consumer Health 548 589 498 Subtotal $ 825 $ 1,366 $ 1,113 Reconciling items to net (loss) earnings Unallocated costs (1) (559) (286) 1 Depreciation and amortization (422) (378) (289) Interest expense, net (186) (123) (110) Income tax benefit (expense) 86 (80) (130) Net (loss) earnings $ (256) $ 499 $ 585 (1) Unallocated costs include restructuring and special items, stock-based compensation, gain (loss) on sale of subsidiary, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows: (Dollars in millions) Fiscal Year Ended June 30, 2023 2022 2021 Impairment charges and gain/loss on sale of assets (a) $ (98) $ (31) $ (9) Stock-based compensation (35) (54) (51) Restructuring and other special items (b) (98) (55) (31) Goodwill impairment charges (c) (210) — — Gain on sale of subsidiary (d) — 1 182 Other income (expense), net (e) 7 (28) (3) Non-allocated corporate costs, net (125) (119) (87) Total unallocated costs $ (559) $ (286) $ 1 (a) For the fiscal year ended June 30, 2023, impairment charges are primarily associated with an idle facility in the Biologics segment and obsolete equipment that could not be sold or repurposed in the Pharma and Consumer Health segment. In the three months ended June 30, 2023, the Company identified an indicator of impairment related to one of its facilities in the Biologics segment given the plans to pause any additional spend on site development due to a lack of demand, leading to a partial impairment charge of $54 million. The Company primarily utilized a market and income approach for real property and a cost approach for personal property to record the partial impairment on its idle facility. Impairment charges are recorded in Other operating expense in the consolidated statements of operations. Also, in the three months ended June 30, 2023, the Company identified an indicator of impairment related to obsolete equipment from a terminated project in the Pharma and Consumer Health segment, leading to a full impairment charge of $18 million. For the fiscal year ended June 30, 2022, impairment charges are primarily due to fixed asset impairment charges associated with dedicated equipment for a product the Company no longer manufactures in its Pharma and Consumer Health segment and obsolete equipment in its Biologics segment. (b) Restructuring and other special items for the fiscal year ended June 30, 2023 includes (i) restructuring charges associated with plans to reduce costs, consolidate facilities, and optimize our infrastructure across the organization and (ii) transaction and integration costs associated with the Metrics acquisition Restructuring and other special items for the fiscal year ended June 30, 2022 include (i) transaction and integration costs primarily associated with the Princeton, Bettera Wellness, Delphi, Hepatic, Acorda, and RheinCell transactions and (ii) unrealized losses on venture capital investments. Restructuring and other special items for the fiscal year ended June 30, 2021 include transaction and integration costs associated with the Anagni, Italy facility acquisition and the MaSTherCell Global, Inc., Skeletal, Delphi, and Acorda transactions, in addition to restructuring costs associated with the closure of the Company's Pharma and Consumer Health facility in Bolton, U.K. (c) The goodwill impairment charges for the fiscal year ended June 30, 2023 was associated with the Company’s Consumer Health reporting unit. For further details, see Note 4, Goodwill . (d) Gain on sale of subsidiary for the fiscal year ended June 30, 2022 was due to the sale of the Company’s facility and Blow-Fill-Seal business in Woodstock, Illinois. (e) Refer to Note 15, Other (income) expense, net for details of financing charges and foreign currency translation adjustments recorded within other (income) expense, net. The following table includes total assets for each segment, as well as reconciling items necessary to total the amounts reported in the consolidated balance sheets. Total Assets (Dollars in millions) June 30, 2023 June 30, 2022 Biologics $ 5,746 $ 5,770 Pharma and Consumer Health 4,867 4,356 Corporate and eliminations 164 382 Total assets $ 10,777 $ 10,508 Capital Expenditures Fiscal Year Ended June 30, (Dollars in millions) 2023 2022 2021 Biologics $ 346 $ 453 $ 516 Pharma and Consumer Health 214 183 151 Corporate 34 30 19 Total capital expenditures $ 594 $ 666 $ 686 Long Lived Assets The following table presents long-lived assets—consisting of property, plant, and equipment, net of accumulated depreciation—by geographic area: (Dollars in millions) June 30, 2023 June 30, 2022 United States $ 2,758 $ 2,267 Europe 765 747 Other 159 113 Total $ 3,682 $ 3,127	[1]
[1]Refer to Note 15, Other (income) expense, net for details of financing charges and foreign currency translation adjustments recorded within other (income) expense, net.

Supplemental Balance Sheet Info

Supplemental Balance Sheet Information	12 Months Ended
	Jun. 30, 2023
Balance Sheet Related Disclosures [Abstract]
Supplemental Balance Sheet Information	SUPPLEMENTAL BALANCE SHEET INFORMATION Supplemental balance sheet information at June 30, 2023 and June 30, 2022 is detailed in the following tables. Inventories Work-in-process and inventories include raw materials, labor, and overhead. Total inventories consist of the following: (Dollars in millions) June 30, June 30, Raw materials and supplies $ 781 $ 651 Work-in-process 186 109 Total inventories, gross 967 760 Inventory cost adjustment (1) (190) (58) Total inventories $ 777 $ 702 (1) Increase in inventory cost adjustment is primarily associated with inventory write-offs resulting from the terminations of certain take-or-pay arrangements. Prepaid expenses and other Prepaid expenses and other current assets consist of the following: (Dollars in millions) June 30, June 30, Prepaid expenses $ 53 $ 61 Short-term contract assets 399 398 Spare parts supplies 24 22 Prepaid income tax 77 27 Non-U.S. value-added tax 38 48 Other current assets 42 70 Total prepaid expenses and other $ 633 $ 626 Property, plant, and equipment, net Property, plant, and equipment, net consist of the following: (Dollars in millions) June 30, June 30, Land, buildings, and improvements $ 1,887 $ 1,687 Machinery and equipment 2,287 1,891 Furniture and fixtures 61 48 Construction in progress 1,043 848 Property, plant, and equipment, at cost 5,278 4,474 Accumulated depreciation (1,596) (1,347) Property, plant, and equipment, net $ 3,682 $ 3,127 Other long-term assets Other long-term assets consist of the following: (Dollars in millions) June 30, June 30, Operating lease right-of-use-assets $ 59 $ 93 Note receivable 53 51 Pension assets 18 37 Corporate-owned life insurance policies 41 35 Venture capital investments 36 33 Interest-rate swap 62 36 Long-term contract assets 18 43 Other 42 21 Total other long-term assets $ 329 $ 349 Other accrued liabilities Other accrued liabilities consist of the following: (Dollars in millions) June 30, June 30, Contract liability $ 167 $ 211 Accrued employee-related expenses 160 198 Accrued expenses 134 140 Operating lease liabilities 11 14 Restructuring accrual 19 1 Accrued interest 35 32 Accrued income tax 44 50 Total other accrued liabilities $ 570 $ 646

Subsequent Events (Notes)

Subsequent Events (Notes)	3 Months Ended
	Dec. 31, 2023
Subsequent Events [Abstract]
Subsequent Events [Text Block]	SUBSEQUENT EVENTS Husty Derivative Claim In August 2023, an alleged shareholder filed a derivative complaint styled Husty et al. v. Carroll, et al. , No. 23-cv-00891, in Delaware federal court against certain current and former members of the Company's board of directors, (the “ Husty Defendants ” ), and nominally against Catalent, Inc. The complaint mimics the allegations set out in the original complaint filed in the City of Warwick Retirement System action described in Note 17, Commitments and Contingencies and claims that the alleged activities described there led to, and will continue to expose the Company to, costs and damages. The Company believes that the Husty Defendants have defenses to the allegations and claims set forth in the complaint and, once all Husty Defendants are properly served with the complaint, intends to vigorously defend the Husty Defendants against such allegations. Brown Derivative Claim In September 2023, an alleged shareholder filed a derivative complaint styled Brown, et al. v. Chiminski, et al. , Case 3:23-cv-15722, in New Jersey federal court against certain current and former officers and members of the Company’s board of directors (the “ Brown Defendants ” ) and nominally against Catalent, Inc. The complaint mimics the allegations set out in the original complaint filed in the City of Warwick Retirement System action described in Note 17, Commitments and Contingencies and claims that the alleged activities described there led to, and will continue to expose the Company to, costs and damages. On November 8, 2023, the Court entered a stipulation between the parties extending the Brown Defendants time to respond to the Complaint until January 8, 2024. The Company believes that the Brown Defendants have defenses to the allegations and claims set forth in the complaint and intends to vigorously defend the Brown Defendants against such allegations. Impairment of Goodwill The Company assessed the current and future economic outlook as of September 30, 2023 for its Consumer Health and Biomodalities reporting units in its Pharma and Consumer Health and Biologics segments, respectively, and identified indicators for impairment of goodwill. The evaluation began with a qualitative assessment of each reporting unit to determine if it was more likely than not that the fair value of the reporting unit was less than its carrying value. The qualitative assessment did not indicate that it was more likely than not that the fair value exceeded the carrying value in its Consumer Health and Biomodalities reporting units, which led to a quantitative assessment for the corresponding reporting units. Interim goodwill tests were not performed on the Company's remaining reporting units as there was no indication of a possible goodwill impairment. For the three months ended September 30, 2023, the Company recorded goodwill impairment charges of $689 million associated with the Company's Consumer Health and Biomodalities reporting units in its Pharma and Consumer Health and Biologics segments, respectively. The impairment charges also generated additional deferred tax assets to the extent of the tax goodwill remaining in the reporting units being impaired. The additional deferred tax assets measured against the deferred tax liabilities at the Company’s domestic sites, along with the Company’s forecast losses triggered in part by the impairment charge itself, resulted in a $53 million valuation allowance to be recorded against the U.S. Federal and state net deferred tax assets for the three months ended September 30, 2023. Amendment No. 9 to Credit Agreement On September 27, 2023, Operating Company entered into Amendment No. 9 to its Amended and Restated Credit Agreement (“Amendment No. 9”) by and among Operating Company, PTS Intermediate, the subsidiaries of Operating Company party thereto, JPMorgan Chase Bank, N.A., as the administrative agent, collateral agent, swing line lender, and letter of credit issuer, and the lenders and other parties thereto, which Amendment No. 9 amends the Credit Agreement to extend the deadlines by which the Operating Company is required to deliver to the administrative agent (i) its audited financial statements as at the end of and for the fiscal year ended June 30, 2023, together with the auditor’s report and opinion on such audited financial statements, to November 27, 2023, and (ii) its unaudited financial statements as at the end of and for the fiscal quarter ending September 30, 2023 to January 13, 2024. Amendment No. 10 to Credit Agreement On November 22, 2023, Operating Company, entered into Amendment No. 10 to its Amended and Restated Credit Agreement (“Amendment No. 10”) by and among Operating Company, PTS Intermediate, the subsidiaries of Operating Company party thereto, JPMorgan Chase Bank, N.A., as the administrative agent, collateral agent, swing line lender, and letter of credit issuer, and the lenders and other parties thereto, which Amendment No. 10 further extends the deadlines by which the Operating Company is required to deliver to the Administrative Agent (i) its audited financial statements as at the end of and for the fiscal year ended June 30, 2023, together with the auditor’s report and opinion on such audited financial statements, to January 26, 2024, and (ii) its unaudited financial statements as at the end of and for the fiscal quarter ending September 30, 2023 to March 13, 2024.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Segment Reporting, Policy	Reportable Segments Effective July 1, 2022, in connection with the appointment of a new President and Chief Executive Officer, the Company changed its operating structure and reorganized its executive leadership team accordingly. The current organizational structure includes two operating and reportable segments—(i) Biologics and (ii) Pharma and Consumer Health—which are summarized below. • The Biologics segment provides development and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA (“pDNA”); induced pluripotent stem cells (“iPSCs”), and oncolytic viruses; and vaccines. It also provides formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; analytical development and testing services for large molecules. • The Pharma and Consumer Health segment comprises the Company’s market-leading capabilities for complex oral solids, softgel formulations, Zydis ® fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms; and clinical trial development and supply services. Each segment reports through a separate management team and ultimately reports to the Company's President and Chief Executive Officer, who is designated as the Chief Operating Decision Maker for segment reporting purposes. The Company's operating segments are the same as its reportable segments. All prior-period comparative segment information has been recast retrospectively to reflect the current reportable segments in accordance with Accounting Standards Codification (“ASC”) 280, Segment Reporting
Basis of Presentation	Basis of Presentation These financial statements include all of the Company’s subsidiaries, including those operating outside the United States ( “ U.S. ” ), and are prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). All significant transactions among the Company’s subsidiaries and reporting segments have been eliminated, other than as noted.
Use of Estimates	Use of Estimates
Reclassifications	Reclassification
Translation and Transaction of Foreign Currencies	Foreign Currency Translation The financial statements of the Company’s operations outside the U.S. are generally determined using the local currency as the functional currency. Adjustments to translate the assets and liabilities of the foreign operations into U.S. dollars are accumulated as a component of other comprehensive income utilizing period-end exchange rates. Since July 2018, the Company has accounted for its Argentine operations as highly inflationary, but this status has not had a material effect on the consolidated financial statements. The currency fluctuation related to certain long-term inter-company loans where settlement is not planned or anticipated in the foreseeable future have been recorded within the cumulative translation adjustment, a component of other comprehensive income. In addition, the currency fluctuation associated with the portion of the Company’s euro-denominated debt designated as a net investment hedge is included as a component of other comprehensive income. Foreign currency transaction gains and losses are calculated using weighted average exchange rates for the period and are included in the consolidated statements of operations in “ other expense, net. ” Such foreign currency transaction gains and losses include inter-company loans that are repayable in the foreseeable future.
Cash and Cash Equivalents	Cash and Cash Equivalents All liquid investments purchased with original maturities of three months or less are considered cash equivalents. The carrying value of these cash equivalents approximates fair value.
Receivables and Allowance dor Doubtful Accounts	Allowance for Credit Losses
Concentrations of Credit Risk and Major Customers	Concentrations of Credit Risk and Major Customers Concentration of credit risk, with respect to accounts receivable, is limited due to the large number of customers and their dispersion across different geographic areas. The customers are primarily concentrated in the biopharmaceutical, pharmaceutical, and consumer products industries. The Company does not normally require collateral or any other security to support credit sales. The Company performs ongoing credit evaluations of its customers’ financial conditions and maintains reserves for credit losses. Such losses historically have been within the Company’s expectations. For the fiscal years ended June 30, 2023 and 2022, the Company had one customer that accounted for 10% of its net revenue, which was primarily recorded in the Biologics segment. No single customer exceeded 10% of revenue during the fiscal year ended June 30, 2021.
Inventories	Inventories
Goodwill	Goodwill The Company accounts for purchased goodwill and intangible assets with indefinite lives in accordance with ASC 350, Intangibles - Goodwill and Other . Under ASC 350, goodwill and intangible assets with indefinite lives are not amortized, but instead are tested for impairment at least annually. The Company performs an impairment evaluation of goodwill an nually during the fourth quarter of its fiscal year or when circumstances otherwise indicate an evaluation should be performed. The evaluation may begin with a qualitative assessment for each reporting unit to determine whether it is more-likely-than-not that the fair value of the reporting unit is less than its carrying value. Factors considered in a qualitative assessment include, among other things, macroeconomic conditions, industry and market considerations, financial performance of the respective reporting unit, and other relevant entity and reporting-unit specific considerations. If the qualitative assessment does not generate a positive response, or if no qualitative assessment is performed, a quantitative assessment, based upon discounted cash flows, is performed and requires management to estimate future cash flows, growth rates, and macroeconomic, industry, and market conditions. The Company performs an annual goodwill impairment test for each reporting unit on April 1, the measurement date. The evaluation begins with a qualitative assessment of each reporting unit to determine if it is more likely than not that the fair value of the reporting unit is less than its carrying value. Due to the Company's underperformance of operating results relative to expectations and decline in the Company's stock price, the Company assessed the current and future economic outlook as of March 31, 2023. The evaluation began with a qualitative assessment of each reporting unit to determine if it was more likely than not that the fair value of the reporting unit was less than its carrying value. The qualitative assessment did not indicate that it was more likely than not that the fair value exceeded the carrying value in each of its six reporting units as of March 31, 2023 which led to a quantitative assessment for each of the Company's reporting units. The evaluation performed as of March 31, 2023 resulted in a goodwill impairment charge in the Company's Consumer Health reporting unit within the Pharma and Consumer Health segment. Subsequent to the quantitative assessment performed as of March 31, 2023, the Company performed a qualitative assessment as of April 1, 2023 which yielded no indicators of impairment. In fiscal 2022, the Company proceeded directly to a quantitative assessment, but, in fiscal 2021, the Company performed its impairment evaluation with a qualitative assessment. The evaluations performed in fiscal 2022 and 2021 resulted in no impairment charge. For more information regarding goodwill activity during fiscal 2022 and 2023 and the related balances at June 30, 2023, see Note 4, Goodwill
Property and Equipment	Property and equipment are stated at cost. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, including leasehold improvements and finance lease right-of-use assets that are amortized over the shorter of their useful lives or the terms of the respective leases. The Company generally uses the following range of useful lives for its property and equipment categories: buildings and improvements—5 to 50 years; machinery and equipment—3 to 10 years; and furniture and fixtures—3 to 7 years. Depreciation expense was $286 million, $255 million, and $196 million for fiscal 2023, 2022, and 2021, respectively. Depreciation expense includes amortization of assets related to financing leases. The Company charges repairs and maintenance costs to expense as incurred. The amount of capitalized interest for fiscal 2023, 2022, and 2021 was $24 million, $15 million, and $17 million, respectively.
Intangible Assets, Finite-Lived	Intangible assets with finite lives, including customer relationships, core technology, patents, and trademarks, are amortized over their useful lives. The Company also capitalizes certain computer software and development costs in other intangibles, net, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 5 years. The Company evaluates the recoverability of its other long-lived assets, including amortizing intangible assets, if circumstances indicate impairment may have occurred pursuant to ASC 360, Property, Plant and Equipment . This analysis is performed by comparing the respective carrying values of the assets to the current and expected future cash flows, on an un-discounted basis, to be generated from such assets. If such analysis indicates that the carrying value of these assets is not recoverable, the carrying value of such assets is reduced to fair value through a charge to the consolidated statements of operations. Fair value is determined based on assumptions the Company believes marketplace participants would utilize and comparable marketplace information in similar arm’s length transactions. In conjunction with the goodwill impairment test performed as of March 31, 2023, the Company identified indicators of impairment related to its definite-lived intangibles. The results of the analysis did not result in an impairment charge.
Post-Retirement and Pension Plans	Post-Retirement and Pension Plans The Company sponsors various retirement and pension plans, including defined benefit and defined contribution retirement plans. The measurement of the related benefit obligations and the net periodic benefit costs recorded each year are based upon actuarial computations, which require management’s judgment as to certain assumptions. These assumptions include the discount rates used in computing the present value of the benefit obligations and the net periodic benefit costs, the expected future rate of salary increases (for pay-related plans) and the expected long-term rate of return on plan assets (for funded plans). The Company uses the corridor approach to amortize actuarial gains and losses. The Company has elected to utilize an approach to estimate the service and interest components of net periodic benefit cost for benefit plans that discounts the individual expected cash flows using the applicable spot rates derived from the yield curve over the projected cash flow period. The expected long-term rate of return on plan assets is based on the target asset allocation and the average expected rate of growth for the asset classes invested. The average expected rate of growth is derived from a combination of historic returns, current market indicators, and the expected risk premium for each asset class. The Company uses a measurement date of June 30 for all its retirement and postretirement benefit plans.
Derivative Instruments and Hedging Activities	Derivative Instruments, Hedging Activities, and Fair Value Derivative Instruments and Hedging Activities The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest-rate, liquidity, and credit risk primarily by managing the amount, sources, and duration of its debt funding and the use of derivative financial instruments. Specifically, the Company enters into derivative financial instruments from time to time to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the values of which are determined by interest rates. The Company’s derivative financial instruments are used to manage differences in the amount, timing, and duration of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s borrowings. The Company does not net any of its derivative positions under master netting arrangements.
Fair Value Measurement, Policy	Fair Value The Company is required to measure certain assets and liabilities at fair value, either upon initial measurement or for subsequent accounting or reporting. The Company uses fair value extensively, including in the initial measurement of net assets acquired in a business combination and when accounting for and reporting on certain financial instruments. The Company estimates fair value using an exit price approach, which requires, among other things, that it determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of assets and, for liabilities, assuming the risk of non-performance will be the same before and after the transfer. A single estimate of fair value results from a complex series of judgments about future events and uncertainties and relies heavily on estimates and assumptions. When estimating fair value, depending on the nature and complexity of the assets or liability, the Company may use one or all of the following approaches: • Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities. • Cost approach, which is based on the cost to acquire or construct comparable assets less an allowance for functional and/or economic obsolescence. • Income approach, which is based on the present value of the future stream of net cash flows. Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
Marketable Securities [Table Text Block]	Marketable Securities The Company classifies its liquid debt investments with original maturities greater than ninety days as marketable securities. The Company invests in highly rated corporate debt securities, with the primary objective of minimizing the potential risk of principal loss. The Company’s investment policy generally requires securities to be investment grade and limits the amount of credit exposure to any single issuer. The Company regularly reviews its investments and utilizes quantitative and qualitative evidence to evaluate potential impairments. For available-for-sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value. If the criteria are not met, the Company evaluates whether the decline in fair value has resulted from a credit loss or other factors. In making this assessment, management considers, among other factors, the extent to which fair value is less than amortized cost, any change to the rating of the security by a rating agency, and adverse conditions specifically related to the security. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of the cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized costs basis. The Company classifies its marketable securities as available-for-sale, because it may sell certain of its marketable securities prior to the stated maturity for various reasons, including management of liquidity, credit risk, duration, relative return, and asset allocation. The Company determines the fair value of each marketable security in its portfolio at each period end and recognizes gains and losses in the portfolio in other comprehensive income. As of June 30, 2023, all of the Company's outstanding marketable securities had matured. The amortized cost basis of all previously owned marketable securities approximated fair value and all previously outstanding marketable securities matured within one year.
Self Insurance	Self-Insurance
Accumulated Other Comprehensive Income/(Loss)	Accumulated Other Comprehensive Loss Accumulated other comprehensive loss, which is reported in the accompanying consolidated statements of changes in shareholders’ equity, consists of foreign currency translation, net change in marketable securities, and defined benefit pension plan changes.
Research and Development Costs	Research and Development Costs
Earnings Per Share	Earnings Per Share The Company reports net earnings per share in accordance with ASC 260, Earnings per Share . Effective as of the first quarter of fiscal 2023, the Company computed earnings per share (“EPS”) of the Company’s common stock, par value $0.01 (the “Common Stock”) using the treasury stock method. Prior to fiscal 2023, the Company computed earnings (loss) per share of the Common Stock using the two-class method required due to the participating nature of the previously outstanding Series A Preferred Stock (as defined and discussed in Note 13, Equity and Accumulated Other Comprehensive Loss ). Diluted earnings per common share measures the performance of the Company over the reporting period while giving effect to all potential shares of Common Stock that were dilutive and outstanding during the period. The denominator includes the weighted average over the measurement period of the sum of the number of shares of Common Stock outstanding and the number of additional such shares that would have been outstanding if the shares of Common Stock that were both potentially issuable and dilutive had been issued.
Income Taxes	Income Taxes In accordance with ASC 740, Income Taxes, the Company accounts for income taxes using the asset and liability method. The asset and liability method requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company’s assets and liabilities. The Company measures deferred tax assets and liabilities using enacted tax rates in the respective jurisdictions in which it operates. In assessing the ability to realize deferred tax assets, the Company considers whether it is more likely than not that the Company will be able to realize some or all of the deferred tax assets. The calculation of the Company’s tax liabilities involves dealing with uncertainties in the application of complex tax regulations in each of its tax jurisdictions. The number of years with open tax audits varies by tax jurisdiction. A number of years may lapse before a particular matter is audited and finally resolved. The Company applies ASC 740 to determine the accounting for uncertain tax positions. This standard prescribes a minimum recognition threshold a tax position is required to meet before the Company may recognize the position in its financial statements. The standard also provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, and disclosure. The Company previously elected not to reclassify the income tax effects stranded in accumulated other comprehensive income to retained earnings.
Equity-Based Compensation	Stock-Based Compensation The Company accounts for its stock-based compensation in accordance with ASC 718, Compensation—Stock Compensation. Under ASC 718, companies recognize compensation expense using a fair-value-based method for costs related to share-based payments, including stock options and restricted stock units. The expense is measured based on the grant date fair value of the awards, and the expense is recorded over the applicable requisite service period. Forfeitures are recognized as and when they occur. In the absence of an observable market price for a share-based award, the fair value is based upon a valuation methodology that takes into consideration various factors, including the exercise price of the award, the expected term of the award, the current price of the underlying shares, the expected volatility of the underlying share price, the expected dividends on the underlying shares and the risk-free interest rate.
Recent Financial Accounting Standards	Recent Financial Accounting Standards In March 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-04, Reference Rate Reform (Topic 848) : Facilitation of the Effects of Reference Rate Reform on Financial Reporting , which provides optional guidance to ease the potential burden in accounting for the discontinuation of a reference rate such as LIBOR, formerly known as the London Interbank Offered Rate, because of reference rate reform. In December 2022, the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848

Revenue from Contract with Cust

Revenue from Contract with Customer (Policies)	12 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer	REVENUE RECOGNITION The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers . The Company generally earns its revenue by supplying goods or providing services under contracts with its customers in three primary revenue streams: manufacturing and commercial product supply, development services, and clinical supply services. The Company measures the revenue from customers based on the consideration specified in its contracts, excluding any sales incentive or amount collected on behalf of a third party, that the Company expects to be entitled to receive in exchange for transferring the promised goods to and/or performing services for the customer (the “Transaction Price”). To the extent the Transaction Price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the Transaction Price utilizing either the expected value method or the most likely amount method, depending on which method is expected to better predict the amount of consideration to which the Company will be entitled. The value of variable consideration is included in the Transaction Price if, and to the extent, it is probable that a significant reversal of the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are re-assessed each reporting period, as required, and any adjustment required is recorded on a cumulative catch-up basis, which would affect revenue and net income in the period of adjustment. The Company’s customer contracts generally include provisions entitling the Company to a termination penalty when the customer terminates prior to the contract’s nominal end date. The termination penalties in customer contracts vary but are generally considered substantive for accounting purposes and create enforceable rights and obligations throughout the stated durations of the contracts. The Company accounts for a contract termination as a contract modification in the period in which the customer gives notice of termination. The determination of the contract termination penalty is based on the terms stated in the relevant customer agreement. As of the modification date, the Company updates its estimate of the Transaction Price using the expected value method, subject to constraints, and to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are re-assessed each reporting period, as required, and any adjustment required is recorded on a cumulative catch-up basis, which would affect revenue and net income in the period of adjustment . Where multiple performance obligations exist in a single contract, the Company allocates consideration to each performance obligation using the “relative standalone selling price” as defined under ASC 606. Generally, the Company utilizes observable standalone selling prices in its allocations of consideration. If observable standalone selling prices are not available, the Company estimates the applicable standalone selling price using a cost-plus-margin approach or an adjusted market assessment approach, in each case, representing the amount that the Company believes the market is willing to pay for the applicable service. Payment is typically due 30 to 45 days following the invoice date, based on the payment terms set forth in the applicable customer agreement. The Company generally expenses sales commissions as incurred because either the amortization period is one year or less, or the balance with an amortization period greater than one year is not material. Customer contracts that include commitments by the Company to make facility space or equipment available may be deemed to include lease components, which are evaluated under ASC 842, Leases . For arrangements that contain both lease and non-lease components, consideration in the contract is allocated on a relative standalone selling-price basis. Determining the lease term and contract term of non-lease components, as well as the variable and fixed consideration in these arrangements, including when variability is resolved, often requires management judgment in order to determine the allocation to the lease and non-lease components. Manufacturing & Commercial Product Supply Revenue Manufacturing and commercial product supply revenue consists of revenue earned by manufacturing products supplied to customers under long-term commercial supply arrangements. In these arrangements, the customer typically owns and supplies the active pharmaceutical ingredient (“API”) or other proprietary materials used in the manufacturing process. The contract generally includes the terms of the manufacturing services and related product quality assurance procedures to comply with regulatory requirements. Due to the regulated nature of the Company’s business, these contract terms are highly interdependent and, therefore, are considered to be a single combined performance obligation. The transaction price is generally stated in the agreement as a fixed price per unit, with no contractual provision for a refund or price concession. In most circumstances, control is transferred to the customer over time, creating a corresponding right to recognize the related revenue, because there is no alternative use to the Company for the asset created and the Company has an enforceable right to payment for performance completed as of that date. The selection of the method for measuring progress towards the completion of the Company’s performance obligation requires judgment and is based on the nature of the products to be manufactured. For the majority of the Company’s arrangements, progress is measured based on the units of product that have successfully completed the contractually required product quality assurance process, because the conclusion of that process defines the time when the applicable contract and the related regulatory requirements permit the customer to exercise control over the product’s disposition. The customer is typically responsible for arranging the shipping and handling of product following completion of the quality assurance process. Payment is typically due 30 to 45 days after invoice date, based on the payment terms set forth in the applicable customer agreement. Beginning in the third quarter of fiscal 2023, the Company began recognizing commercial revenue for certain contracts in its Biologics segment that have a notably long manufacturing cycle, and for which the customer exercises control over the product throughout the manufacturing process. For these contracts, revenue is recognized over time and progress is measured using an input method based on effort expended, which provides an appropriate depiction of the Company’s progress toward fulfilling its performance obligation. Development Services and Clinical Supply Revenue Development services contracts generally take the form of short-term, fee-for-service arrangements. Performance obligations vary, but frequently include biologic cell-line development, performing formulation, analytical stability, or other services related to product development, and providing manufacturing services for products that are under development or otherwise not intended for commercial sale. They can also include a combination of the following services: the manufacturing, packaging, storage, distribution, destruction, and inventory management of customer clinical trial material, as well as the sourcing of comparator drug products on behalf of customers to be used in clinical trials to compare performance with the drug under clinical investigation. The transaction prices for these arrangements are fixed and include amounts stated in the contracts for each promised service, and each service is generally considered to be a separate performance obligation. In most instances, the Company recognizes revenue over time because there is no alternative use to the Company for the asset created and the Company has an enforceable right to payment for performance completed as of that date. The Company measures progress toward the completion of its performance obligations satisfied over time based on the nature of the services to be performed. For certain types of arrangements, revenue is recognized over time and measured using an output method based on the completion of tasks and activities that are performed to satisfy a performance obligation. For certain types of arrangements, revenue is recognized over time and measured using an input method based on effort expended. Each of these methods provides an appropriate depiction of the Company’s progress toward fulfilling its performance obligations for its respective arrangement. In certain development services arrangements that require a portion of the contract consideration to be received in advance at the commencement of the contract, such advance payment is initially recorded as a contract liability. In certain clinical supply arrangements, revenue is recognized at the point in time when control transfers, which occurs upon either the delivery of the related output of the service to the customer or the completion of quality testing with respect to the product, and the Company has an enforceable right to payment based on the terms of the arrangement. The Company records revenue for comparator sourcing arrangements on a net basis because it is acting as an agent that does not control the product or service before it is transferred to the customer. Payment for comparator sourcing activity is typically received in advance at the commencement of the contract and is initially recorded as a contract liability. The Company generally expenses sales commissions as incurred because either the amortization period is one year or less, or the balance with an amortization period greater than one year is not material. The following tables reflect net revenue for the fiscal years ended June 30, 2023, 2022, and 2021 by type of activity and reporting segment (in millions): Fiscal Year Ended June 30, 2023 Biologics Pharma and Consumer Health Total Manufacturing & commercial product supply $ 450 $ 1,452 $ 1,902 Development services & clinical supply 1,528 835 2,363 Total $ 1,978 $ 2,287 $ 4,265 Inter-segment revenue elimination (2) Combined net revenue $ 4,263 Fiscal Year Ended June 30, 2022 Biologics Pharma and Consumer Health Total Manufacturing & commercial product supply $ 608 $ 1,474 $ 2,082 Development services & clinical supply 1,926 797 2,723 Total $ 2,534 $ 2,271 $ 4,805 Inter-segment revenue elimination (3) Combined net revenue $ 4,802 Fiscal Year Ended June 30, 2021 Biologics Pharma and Consumer Health Total Manufacturing & commercial product supply $ 532 $ 1,321 $ 1,853 Development services & clinical supply 1,406 742 2,148 Total $ 1,938 $ 2,063 $ 4,001 Inter-segment revenue elimination (3) Combined net revenue $ 3,998 The following table reflects net revenue by the location where the goods were made or the service performed: (Dollars in millions) Fiscal Year Ended Fiscal Year Ended Fiscal Year Ended United States $ 2,768 $ 3,084 $ 2,462 Europe 1,257 1,506 1,343 Other 355 327 288 Elimination of revenue attributable to multiple locations (117) (115) (95) Total $ 4,263 $ 4,802 $ 3,998 Contract Liabilities Contract liabilities relate to cash consideration that the Company receives in advance of satisfying the related performance obligations. The contract liabilities balances (current and non-current) as of June 30, 2023 and June 30, 2022 were as follows: (Dollars in millions) Balance at June 30, 2022 $ 220 Balance at June 30, 2023 $ 180 Revenue recognized in the period from amounts included in contracts liability at the beginning of the period: $ 126 Contract liabilities that will be recognized within 12 months of June 30, 2023 are accounted for in Other accrued liabilities and those that will be recognized longer than 12 months after June 30, 2023 are accounted for within Other liabilities. Contract Assets Contract assets primarily relate to the Company's conditional right to receive consideration for services that have been performed for customers but had not yet been invoiced as of June 30, 2023. Contract assets are transferred to trade receivables, net when the Company’s right to receive the consideration becomes unconditional. Contract assets totaled $417 million and $441 million as of June 30, 2023 and 2022, respectively. Contract assets expected to transfer to trade receivables within 12 months are accounted for within Prepaid expenses and other. Contract assets expected to transfer to trade receivables after 12 months are accounted for within Other long-term assets. As of June 30, 2023, the Company recorded no reserve against any of its contract asset balances. Performance Obligations Remaining performance obligations represent firm orders for future development services as well as manufacturing and commercial product supply, including minimum volume commitments, for which there are incomplete performance obligations for work not yet completed under executed contracts. Remaining performance obligations as of June 30, 2023 were $335 million. The Company expects to recognize approximately 42% of the remaining performance obligations in existence as of June 30, 2023 after June 30, 2024.

Revenue Recognition (Tables)

Revenue Recognition (Tables) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Line Items]
Disaggregation of Revenue	The following tables reflect net revenue for the fiscal years ended June 30, 2023, 2022, and 2021 by type of activity and reporting segment (in millions): Fiscal Year Ended June 30, 2023 Biologics Pharma and Consumer Health Total Manufacturing & commercial product supply $ 450 $ 1,452 $ 1,902 Development services & clinical supply 1,528 835 2,363 Total $ 1,978 $ 2,287 $ 4,265 Inter-segment revenue elimination (2) Combined net revenue $ 4,263 Fiscal Year Ended June 30, 2022 Biologics Pharma and Consumer Health Total Manufacturing & commercial product supply $ 608 $ 1,474 $ 2,082 Development services & clinical supply 1,926 797 2,723 Total $ 2,534 $ 2,271 $ 4,805 Inter-segment revenue elimination (3) Combined net revenue $ 4,802
Net revenue	$ 4,263	$ 4,802	$ 3,998
Elimination of revenue attributable to multiple locations	$ (117)	(115)	(95)
Revenue Recognition and Deferred Revenue [Abstract]
Contractual Liabilities	The contract liabilities balances (current and non-current) as of June 30, 2023 and June 30, 2022 were as follows: (Dollars in millions) Balance at June 30, 2022 $ 220 Balance at June 30, 2023 $ 180 Revenue recognized in the period from amounts included in contracts liability at the beginning of the period: $ 126
geographical [Member]
Disaggregation of Revenue [Line Items]
Disaggregation of Revenue	The following table reflects net revenue by the location where the goods were made or the service performed: (Dollars in millions) Fiscal Year Ended Fiscal Year Ended Fiscal Year Ended United States $ 2,768 $ 3,084 $ 2,462 Europe 1,257 1,506 1,343 Other 355 327 288 Elimination of revenue attributable to multiple locations (117) (115) (95) Total $ 4,263 $ 4,802 $ 3,998
United States [Member]
Disaggregation of Revenue [Line Items]
Net revenue	$ 2,768	3,084	2,462
Europe
Disaggregation of Revenue [Line Items]
Net revenue	1,257	1,506	1,343
International Other
Disaggregation of Revenue [Line Items]
Net revenue	$ 355	$ 327	$ 288

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Carrying Amount of Goodwill	The following table summarizes the changes from June 30, 2021 to June 30, 2022 and then to June 30, 2023 in the carrying amount of goodwill in total and by reportable segment: (Dollars in millions) Biologics Pharma and Consumer Health Total Balance at June 30, 2021 $ 1,562 $ 957 $ 2,519 Additions (1) 41 531 572 Foreign currency translation adjustments (37) (48) (85) Balance at June 30, 2022 1,566 1,440 3,006 Additions (2) — 219 219 Reallocation (15) 15 — Foreign currency translation adjustments 12 12 24 Impairment (3) — (210) (210) Balance at June 30, 2023 $ 1,563 $ 1,476 $ 3,039 (1) The additions to goodwill arise from the Bettera Wellness (Pharma and Consumer Health), Princeton (Biologics), RheinCell (Biologics), and Delphi (Biologics) acquisitions. For further details, see Note 3, Business Combinations and Divestitures . (2) The addition to goodwill is a result of the Metrics acquisition. For further details, see Note 3, Business Combinations and Divestitures . (3) Represents gross and accumulated impairment charges.

Definite Lived Long-Lived Ass_2

Definite Lived Long-Lived Assets (Tables)	12 Months Ended
	Jun. 30, 2023
Finite lived intangible assets disclosure [Abstract]
Other Intangible Assets Subject to Amortization	The details of other intangible assets subject to amortization as of June 30, 2023 and June 30, 2022 are as follows (in millions): June 30, 2023 Weighted Average Life Gross Carrying Value Accumulated Amortization Net Carrying Value Amortized intangibles: Core technology 11 years $ 482 $ (164) $ 318 Customer relationships 13 years 1,079 (451) 628 Product relationships 8 years 243 (216) 27 Other 5 years 24 (17) 7 Total other intangibles $ 1,828 $ (848) $ 980 June 30, 2022 Weighted Average Life Gross Carrying Value Accumulated Amortization Net Carrying Value Amortized intangibles: Core technology 11 years $ 480 $ (121) $ 359 Customer relationships 13 years 1,020 (366) 654 Product relationships 8 years 239 (204) 35 Other 4 years 24 (12) 12 Total other intangibles $ 1,763 $ (703) $ 1,060
Future Amortization Expense	Future amortization expense is estimated to be: (Dollars in millions) 2024 2025 2026 2027 2028 Thereafter Total Amortization $ 137 $ 134 $ 126 $ 109 $ 101 $ 373 $ 980

Restructuring and Other Costs (

Restructuring and Other Costs (Tables)	12 Months Ended
	Jun. 30, 2023
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Other Costs	The following tables summarize the restructuring costs by type of cost and reportable segment: Fiscal Year Ended June 30, (Dollars in millions) 2023 2022 2021 Restructuring costs: Employee-related reorganization $ 38 $ 9 $ 8 Facility exit and other costs 28 1 2 Total restructuring costs $ 66 $ 10 $ 10 Fiscal Year Ended June 30, (Dollars in millions) 2023 2022 2021 Restructuring costs: Biologics $ 41 $ 1 $ — Pharma and Consumer Health 8 5 9 Non-segment (Corporate) 17 4 1 Total restructuring costs $ 66 $ 10 $ 10 The following tables illustrates the change in the employee separation-related liability associated with the plans. (Dollars in millions) Employee-related restructuring Balance, June 30, 2022 $ 1 Charges to income 38 Payments (20) Balance, June 30, 2023 $ 19

Long-Term Obligations and Other

Long-Term Obligations and Other Short-Term Borrowings (Tables)	12 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Maturities of long-term obligations	Maturities of long-term obligations, including finance leases of $341 million, and other short-term borrowings for future fiscal years are: (Dollars in millions) 2024 2025 2026 2027 2028 Thereafter Total Maturities of long-term and other obligations $ 536 $ 48 $ 31 $ 32 $ 1,429 $ 2,812 $ 4,888
Fair Value Disclosures [Abstract]
Schedule Of Carrying And Fair Value Of Financial Instruments Table	The carrying amounts and the estimated fair values of financial instruments as of June 30, 2023 and June 30, 2022 are as follows: June 30, 2023 June 30, 2022 (Dollars in millions) Fair Value Measurement Carrying Value Estimated Fair Value Carrying Value Estimated Fair Value 5.000% Senior Notes due 2027 Level 2 $ 500 $ 482 $ 500 $ 483 2.375% euro Senior Notes due 2028 Level 2 904 784 874 744 3.125% Senior Notes due 2029 Level 2 550 481 550 476 3.500% senior notes due 2030 Level 2 650 566 650 561 Senior secured credit facilities & other Level 2 2,284 2,141 1,669 1,575 Subtotal $ 4,888 $ 4,454 $ 4,243 $ 3,839 Unamortized discount and debt issuance (39) — (41) — Total debt $ 4,849 $ 4,454 $ 4,202 $ 3,839

Earnings Per Share Calculation

Earnings Per Share Calculation (Tables)	12 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The reconciliations between basic and diluted EPS attributable to Catalent common shareholders for the fiscal years ended June 30, 2023, 2022, and 2021 are as follows: Fiscal year ended June 30, (In millions, except per share data) 2023 2022 2021 Net earnings $ (256) $ 499 $ 585 Less: Net earnings attributable to preferred shareholders — (16) (56) Net earnings attributable to common shareholders $ (256) $ 483 $ 529 Weighted average shares outstanding - basic 181 176 168 Weighted average dilutive securities issuable - stock plans — 2 2 Total weighted average shares outstanding - diluted 181 178 170 (Loss) earnings per share: Basic $ (1.42) $ 2.74 $ 3.15 Diluted $ (1.42) $ 2.73 $ 3.11
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The diluted weighted average number of shares outstanding for the fiscal years ended June 30, 2023, 2022, and 2021 did not include the following weighted average number of shares of Common Stock associated with the formerly outstanding Series A Preferred Stock or the weighted average number of shares of Common Stock associated with outstanding equity grants due to their antidilutive effect: Fiscal year ended June 30, (share counts in millions) 2023 2022 2021 Series A Preferred Stock — 3 10

Derivative Instruments and He_2

Derivative Instruments and Hedging Activities (Tables)	12 Months Ended
	Jun. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Net Investment Hedge in Accumulated Other Comprehensive Income (Loss) and Statement of Financial Performance [Table Text Block]	The following table includes net investment hedge activity during the fiscal years ended June 30, 2023 and 2022, respectively: (Dollars in millions) June 30, 2023 June 30, 2022 Unrealized foreign exchange gain (loss) within other comprehensive income $ (30) $ 121 Unrealized foreign exchange loss within statement of operations $ — $ (11)
Schedule of Interest Rate Derivatives	A summary of the estimated fair value of the interest-rate swap reported in the consolidated balance sheets is stated in the table below: June 30, 2023 June 30, 2022 (in millions) Balance Sheet Classification Estimated Fair Value Balance Sheet Classification Estimated Fair Value Interest-rate swap Other long-term assets $ 62 Other long-term assets $ 36

Fair Value Measures and Discl_2

Fair Value Measures and Disclosures (Tables)	12 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table sets forth the Company’s financial assets and liabilities that were measured at fair value on a recurring basis and the fair value measurement for such assets and liabilities at June 30, 2023 and 2022, respectively: (Dollars in millions) Basis of Fair Value Measurement June 30, 2023 Total Level 1 Level 2 Level 3 Assets: Interest-rate swap $ 62 $ — $ 62 $ — Trading securities $ 1 $ 1 $ — $ — June 30, 2022 Assets: Marketable securities $ 89 $ 89 $ — $ — Interest-rate swap 36 — 36 — Trading securities $ 2 $ 2 $ — $ —

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Earnings/(loss) from continuing operations before income taxes and discontinued operations	Earnings before income taxes are as follows for fiscal 2023, 2022, and 2021: Fiscal Year Ended (Dollars in millions) 2023 2022 2021 U.S. operations $ (410) $ 224 $ 457 Non-U.S. operations 68 355 258 Total $ (342) $ 579 $ 715
Provision/ (benefit) for income taxes	The provision for income taxes consists of the following for fiscal 2023, 2022, and 2021: Fiscal Year Ended (Dollars in millions) 2023 2022 2021 Current: Federal $ (1) $ (8) $ 8 State and local (1) 14 20 Non-U.S. 43 66 38 Total current expense $ 41 $ 72 $ 66 Deferred: Federal $ (99) $ 6 $ 62 State and local (4) (5) 7 Non-U.S. (24) 7 (5) Total deferred (benefit) expense $ (127) $ 8 $ 64 Total (benefit) provision $ (86) $ 80 $ 130
Reconciliation of the provision/(benefit) based on the federal statutory income tax rate	A reconciliation of the provision starting from the tax computed at the federal statutory income tax rate to the tax computed at the Company’s effective income tax rate is as follows for the fiscal years ended 2023, 2022, and 2021: Fiscal Year Ended (Dollars in millions) 2023 2022 2021 Provision at U.S. federal statutory tax rate $ (72) $ 122 $ 150 State and local income taxes (13) 10 26 Foreign tax rate differential (5) (28) (14) Global intangible low tax income 2 6 3 Other permanent items 13 2 (5) Unrecognized tax positions (1) 1 3 Tax valuation allowance 5 94 (7) Foreign tax credit (30) (43) (24) Withholding tax and other foreign taxes 1 1 1 Change in tax rate 18 1 2 R&D tax credit (3) (2) (5) Swiss tax reform — (83) — Other (1) (1) — Total provision $ (86) $ 80 $ 130
Components of the deferred income tax assets and liabilities	Deferred income taxes arise from temporary differences between the financial reporting and tax reporting bases of assets and liabilities, and operating loss and tax credit carryforwards for tax purposes. The components of the Company's deferred income tax assets and liabilities are as follows at June 30, 2023 and 2022: Fiscal Year Ended (Dollars in millions) 2023 2022 Deferred income tax assets: Accrued liabilities $ 57 $ 33 Equity compensation 13 14 Loss and tax credit carryforwards 287 230 Foreign currency 3 19 Pension 19 17 Interest-related 50 14 Deferred revenue — 1 Lease liabilities 38 39 Euro-denominated debt 1 — Other 1 2 Total deferred income tax assets $ 469 $ 369 Valuation allowance (159) (149) Net deferred income tax assets $ 310 $ 220 Fiscal Year Ended (Dollars in millions) 2023 2022 Deferred income tax liabilities: Euro-denominated debt $ — $ (6) Property-related (247) (227) Goodwill and other intangibles (71) (113) Right-of-use assets (13) (21) Other — (1) Total deferred income tax liabilities $ (331) $ (368) Net deferred tax liability $ (21) $ (148)
Deferred tax assets and liabilities	Deferred tax assets and liabilities in the preceding table are in the following captions in the consolidated balance sheets at June 30, 2023 and 2022: Fiscal Year Ended (Dollars in millions) 2023 2022 Non-current deferred tax asset $ 55 $ 49 Non-current deferred tax liability (76) (197) Net deferred tax liability $ (21) $ (148)
Reconciliation of Unrecognized tax benefit, excluding accrued interest	A reconciliation of unrecognized tax benefits, excluding accrued interest, as of June 30, 2023, 2022, and 2021 is as follows: (Dollars in millions) Balance at June 30, 2020 $ 4 Additions for tax positions of prior years 3 Lapse of the applicable statute of limitations (2) Balance at June 30, 2021 $ 5 Additions for tax positions related to the current year 1 Additions for tax positions of prior years 1 Settlements (1) Lapse of the applicable statute of limitations (1) Balance at June 30, 2022 $ 5 Additions for tax positions of prior years 2 Reductions for tax positions of prior years (1) Settlements (1) Lapse of the applicable statute of limitations (1) Balance at June 30, 2023 $ 4

Employee Retirement Benefit P_2

Employee Retirement Benefit Plans (Tables)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Retirement Benefits [Abstract]
Benefit obligation and fair value of plan assets for the defined benefit retirement and postretirement plan	The following table provides a reconciliation of the change in projected benefit obligation and fair value of plan assets for the defined benefit retirement and other retirement plans, excluding the multi-employer pension plan liability: Retirement Benefits Other Post-Retirement Benefits June 30, June 30, (Dollars in millions) 2023 2022 2023 2022 Accumulated Benefit Obligation $ 242 $ 262 $ 2 $ 2 Change in Benefit Obligation Benefit obligation at beginning of year 268 372 2 2 Company service cost 3 4 — — Interest cost 9 5 — — Employee contributions 1 — — — Settlements (4) (1) — — Benefits paid (10) (9) — — Actuarial gain (1) (28) (71) — — Exchange rate gain (loss) 7 (32) — — Benefit obligation at end of year $ 246 $ 268 $ 2 $ 2 Change in Plan Assets Fair value of plan assets at beginning of year 240 318 — — Actual return on plan assets (38) (50) — — Company contributions 7 10 — — Employee contributions 1 — — — Settlements (4) (1) — — Benefits paid (10) (9) — — Exchange rate gain (loss) 6 (28) — — Fair value of plan assets at end of year $ 202 $ 240 $ — $ — Funded Status Funded status at end of year (44) (28) (2) (2) Net pension liability $ (44) $ (28) $ (2) $ (2)
Reconciliation of the net amount recognized in the Consolidated Balance Sheets	The following table provides a reconciliation of the net amount recognized in the consolidated balance sheets: Retirement Benefits Other Post-Retirement Benefits June 30, June 30, (Dollars in millions) 2023 2022 2023 2022 Amounts Recognized in Statement of Financial Position Noncurrent assets $ 18 $ 37 $ — $ — Current liabilities (1) (1) — — Noncurrent liabilities (61) (64) (2) (2) Total liability (44) (28) (2) (2) Amounts Recognized in Accumulated Other Comprehensive Loss Prior service cost (1) (1) — — Net loss (gain) 66 49 (1) (1) Total accumulated other comprehensive loss (income) at the end of the fiscal year 65 48 (1) (1) Additional Information for Plan with ABO or PBO in Excess of Plan Assets Projected benefit obligation 129 132 2 2 Accumulated benefit obligation 126 128 2 2 Fair value of plan assets 68 67 — — Components of Net Periodic Benefit Cost Service cost 3 4 — — Interest cost 9 5 — — Expected return on plan assets (9) (10) — — Amortization of unrecognized: Net loss 1 2 — — Settlement/curtailment expense 1 — — — Net periodic benefit cost $ 5 $ 1 $ — $ — Retirement Benefits Other Post-Retirement Benefits June 30, June 30, (Dollars in millions) 2023 2022 2023 2022 Other Changes in Plan Assets and Benefit Obligations Recognized in Other Comprehensive Income Net loss (gain) arising during the year $ 17 $ (14) $ — $ — Exchange rate loss recognized during the year — 1 — — Total recognized in other comprehensive income $ 17 $ (13) $ — $ — Total Recognized in Net Periodic Benefit Cost and Other Comprehensive Income Total recognized in net periodic benefit cost and other comprehensive income $ 22 $ (12) $ — $ — Estimated Amounts to be Amortized from Accumulated Other Comprehensive Income into Net Periodic Benefit Cost Amortization of: Net loss $ 2 $ 1 $ — $ — Financial Assumptions Used to Determine Benefit Obligations at the Balance Sheet Date Discount rate (%) 4.3 % 3.6 % 4.7 % 4.0 % Rate of compensation increases (%) 2.7 % 2.7 % n/a n/a Financial Assumptions Used to Determine Net Periodic Benefit Cost for Financial Year Discount rate (%) 3.6 % 1.6 % 4.0 % 2.0 % Rate of compensation increases (%) 2.7 % 2.0 % n/a n/a Expected long-term rate of return (%) 3.9 % 3.4 % n/a n/a Expected Future Contributions Fiscal year 2024 $ 8 $ 7 $ — $ — Retirement Benefits Other Post-Retirement Benefits June 30, June 30, (Dollars in millions) 2023 2022 2023 2022 Expected Future Benefit Payments Financial year 2024 $ 14 $ 14 $ — $ — 2025 15 13 — — 2026 16 14 — — 2027 15 16 — — 2028 15 14 — — 2029-2033 84 80 1 1 Actual Asset Allocation (%) Cash 4.5 % — % — % — % Equities 2.9 % 4.1 % — % — % Government bonds 36.8 % 35.6 % — % — % Corporate bonds 16.2 % 18.3 % — % — % Property 3.3 % 4.9 % — % — % Insurance contracts 14.9 % 12.0 % — % — % Other 21.4 % 25.1 % — % — % Total 100.0 % 100.0 % — % — % Actual Asset Allocation (Amount) Cash $ 9 $ — $ — $ — Equities 6 10 — — Government bonds 74 85 — — Corporate bonds 33 44 — — Property 7 12 — — Insurance contracts 30 29 — — Other 43 60 — — Total $ 202 $ 240 $ — $ — Target Asset Allocation (%) Cash 4.5 % — % — % — % Equities 2.9 % 4.1 % — % — % Government bonds 36.8 % 35.6 % — % — % Corporate bonds 16.2 % 18.3 % — % — % Property 3.3 % 4.9 % — % — % Insurance contracts 14.9 % 12.0 % — % — % Other 21.4 % 25.1 % — % — % Total 100.0 % 100.0 % — % — %
Summary of plan assets that are measured in fair value	The following tables provide a summary of plan assets that are measured at fair value as of June 30, 2023 and 2022, aggregated by the level in the fair value hierarchy within which those measurements fall: As of June 30, 2023 (dollars in millions) Level 1 Level 2 Level 3 Investments Measured at Net Asset Value Total Assets Equity securities $ — $ 6 $ — $ — $ 6 Debt securities — 107 — — 107 Real estate — 5 2 — 7 Other (1) — 57 25 — 82 Total $ — $ 175 $ 27 $ — $ 202 (1) Other, as of June 30, 2023, included $20 million of investments in hedge funds related to the Company's U.K. pension plan, which were classified as Level 2.	As of June 30, 2022 (dollars in millions) Level 1 Level 2 Level 3 Investments Measured at Net Asset Value Total Assets Equity securities $ — $ 10 $ — $ — $ 10 Debt securities — 129 — — 129 Real estate — 10 2 — 12 Other (1) — 64 25 — 89 Total $ — $ 213 $ 27 $ — $ 240
Reconciliation of beginning and ending balances of level 3 assets	The following table provides a reconciliation of the beginning and ending balances of Level 3 assets as well as the changes during the period attributable to assets held and those purchases, sales, settlements, contributions, and benefits that were paid: Fair Value Measurement Using Significant Unobservable Inputs Total (Level 3) Fair Value Measurement Using Significant Unobservable Inputs Insurance Contracts Fair Value Measurement Using Significant Unobservable Inputs Other Total (Level 3) (Dollars in millions) Beginning Balance at June 30, 2022 $ 27 $ 9 $ 18 Actual return on plan assets: Relating to assets still held at the reporting date 2 — 2 Purchases, sales, settlements, contributions and benefits paid (3) (1) (2) Transfers in or out of Level 3, net 1 — 1 Ending Balance at June 30, 2023 $ 27 $ 8 $ 19
Assumed healthcare cost trend rates	Other Post-Retirement Benefits Assumed Healthcare Cost Trend Rates at the Balance Sheet Date 2023 2022 Healthcare cost trend rate – initial (%) Pre-65 n/a n/a Post-65 4.8 % 4.6 % Healthcare cost trend rate – ultimate (%) Pre-65 n/a n/a Post-65 4.1 % 4.1 % Year in which ultimate rates are reached Pre-65 n/a n/a Post-65 2040 2040

Equity and Accumulated Other Co

Equity and Accumulated Other Comprehensive Income (Loss) (Tables)	12 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Accumulated other comprehensive earnings/(loss)	or the fiscal years ended June 30, 2023, 2022, and 2021, the changes in accumulated other comprehensive loss, net of tax by component are as follows: (Dollars in millions) Foreign Currency Translation Adjustment Pension Liability Adjustments Derivatives and Hedges Marketable Securities Other Total Balance at June 30, 2020 $ (335) $ (47) $ (3) $ — $ (1) $ (386) Other comprehensive loss before reclassifications 67 — 3 (1) — 69 Balance at June 30, 2021 (268) (47) — (1) (1) (317) Other comprehensive income (loss) before reclassifications (110) 8 27 (3) — (78) Amounts reclassified from other comprehensive loss — 1 — — — 1 Balance at June 30, 2022 (378) (38) 27 (4) (1) (394) Other comprehensive income (loss) before reclassifications 32 (16) 18 — — 34 Amounts reclassified from other comprehensive loss — 2 — 4 — 6 Balance at June 30, 2023 $ (346) $ (52) $ 45 $ — $ (1) $ (354)
Schedule of Comprehensive Income (Loss)	The components of the changes in the cumulative translation adjustment, derivatives and hedges, minimum pension liability, and marketable securities for the fiscal years ended June 30, 2023, 2022, and 2021 are presented below: Fiscal Year Ended June 30, (Dollars in millions) 2023 2022 2021 Foreign currency translation adjustments: Net investment hedge $ (30) $ 121 $ (56) Long-term inter-company loans 12 (37) 39 Translation adjustments 43 (169) 72 Total foreign currency translation adjustments, pretax 25 (85) 55 Tax (benefit) expense (7) 25 (12) Total foreign currency translation adjustments, net of tax $ 32 $ (110) $ 67 Net change in derivatives and hedges: Net gain recognized during the year, pretax $ 25 $ 36 $ 4 Tax expense 7 9 1 Net change in derivatives and hedges, net of tax $ 18 $ 27 $ 3 Net change in minimum pension liability: Net (loss) gain recognized during the year, pretax $ (17) $ 13 $ — Tax (benefit) expense (3) 4 — Net change in minimum pension liability, net of tax $ (14) $ 9 $ — Net change in marketable securities: Net gain (loss) recognized during the year, pretax $ 5 $ (3) $ (1) Tax expense 1 — — Net change in marketable securities, net of tax $ 4 $ (3) $ (1) For the fiscal years ended June 30, 2023, 2022, and 2021, the changes in accumulated other comprehensive loss, net of tax by component are as follows: (Dollars in millions) Foreign Currency Translation Adjustment Pension Liability Adjustments Derivatives and Hedges Marketable Securities Other Total Balance at June 30, 2020 $ (335) $ (47) $ (3) $ — $ (1) $ (386) Other comprehensive loss before reclassifications 67 — 3 (1) — 69 Balance at June 30, 2021 (268) (47) — (1) (1) (317) Other comprehensive income (loss) before reclassifications (110) 8 27 (3) — (78) Amounts reclassified from other comprehensive loss — 1 — — — 1 Balance at June 30, 2022 (378) (38) 27 (4) (1) (394) Other comprehensive income (loss) before reclassifications 32 (16) 18 — — 34 Amounts reclassified from other comprehensive loss — 2 — 4 — 6 Balance at June 30, 2023 $ (346) $ (52) $ 45 $ — $ (1) $ (354)

Equity Based Compensation (Tabl

Equity Based Compensation (Tables)	12 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]	The weighted average of assumptions used in estimating the fair value of stock options granted during each year were as follows: Fiscal Year Ended June 30, 2023 2022 2021 Expected volatility 37% 37% 27% Expected life (in years) 4.3 3.7 6.25 Risk-free interest rate 3.2% 0.7% 0.3% Dividend yield None None None
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	The following table summarizes stock option activity and shares subject to outstanding options for the fiscal year ended June 30, 2023 : Weighted Average Exercise Price Number of Shares Weighted Average Contractual Term Aggregate Intrinsic Value Outstanding as of June 30, 2022 $ 63.74 1,055,511 6.91 $ 47,013,454 Granted 104.84 151,454 — — Exercised 35.17 114,922 — 3,293,593 Forfeited 94.34 62,729 — — Expired / Canceled 67.37 20,567 — — Outstanding as of June 30, 2023 71.19 1,008,747 6.22 2,225,819 Vested/expected to vest as of June 30, 2023 71.19 1,008,747 6.22 2,225,819 Vested and exercisable as of June 30, 2023 $ 54.62 596,627 5.23 $ 2,225,819
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	The following table summarizes activity in unvested time-based restricted stock units and restricted stock for the fiscal year ended June 30, 2023: Time-Based Units and Shares Weighted Average Grant-Date Fair Value Unvested as of June 30, 2022 722,438 $ 91.42 Granted 719,028 72.56 Vested 251,943 66.84 Cancelled/forfeited 162,794 96.53 Unvested as of June 30, 2023 1,026,729 83.07
Schedule of Nonvested Performance-based Units Activity [Table Text Block]	Adjusted EPS and RTSR-Based Performance Share Units and Performance Shares The following table summarizes activity in unvested performance share units and performance shares for the fiscal year ended June 30, 2023: Performance-Based Units and Shares Weighted Average Grant-Date Fair Value Target Number Unvested as of June 30, 2022 305,746 $ 83.75 Target Number Granted 250,232 98.49 Target Number Vested 228,129 55.03 Target Number Cancelled/forfeited 53,864 102.28 Target Number Unvested as of June 30, 2023 273,985 $ 99.58
Fair Value Measurements, Nonrecurring	Valuation of RTSR Performance Shares and Performance Share Units The fair value of each RTSR performance share unit is determined using the Monte Carlo pricing model because the number of shares to be awarded is subject to a market condition. The Monte Carlo simulation is a generally accepted statistical technique used to simulate a range of possible future outcomes. Because the valuation model considers a range of possible outcomes, compensation cost is recognized regardless of whether the market condition is actually satisfied. The assumptions used in estimating the fair value of the RTSR performance share units granted during each year were as follows: Fiscal Year Ended June 30, 2023 2022 Expected volatility 41 % - 47% 39 % - 41% Expected life (in years) 2.4 - 2.9 2.4 - 2.9 Risk-free interest rates 3.0 % - 4.6% 0.3 % - 1.5% Dividend yield None None
Nonvested Restricted Stock Shares Activity	The following table summarizes activity in unvested RTSR performance share units and performance shares for the fiscal year ended June 30, 2023. RTSR Units and Shares Weighted Average Grant-Date Fair Value Target Number Unvested as of June 30, 2022 281,315 $ 91.04 Target Number Granted 271,538 65.69 Target Number Vested 149,786 62.89 Target Number Cancelled/forfeited 60,521 93.64 Target Number Unvested as of June 30, 2023 342,546 $ 82.36

Leases (Tables)

Leases (Tables)	12 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Schedule of Operating and Financing Leases Presented in Balance Sheet	Supplemental information concerning the leases recorded in the Company's consolidated balance sheet as of June 30, 2023 is detailed in the following table: (Dollars in millions) Line item in the consolidated balance sheet Balance at Right-of-use assets: Finance leases Property, plant, and equipment, net $ 274 Operating leases Other long-term assets 59 Current lease liabilities: Finance leases Current portion of long-term obligations and other short-term borrowings 18 Operating leases Other accrued liabilities 11 Non-current lease liabilities: Finance leases Long-term obligations, less current portion 323 Operating leases Other liabilities $ 55
Lease, Cost	The components of the net lease costs for the fiscal year ended June 30, 2023 reflected in the Company's consolidated statement of operations were as follows: (Dollars in millions) Fiscal Year Ended Financing lease costs: Amortization of right-of-use assets $ 21 Interest on lease liabilities 17 Total 38 Operating lease costs 35 Variable lease costs 10 Total lease costs $ 83 The short-term lease cost amounted to $10 million during the fiscal year ended June 30, 2023. The weighted average remaining lease term and weighted average discount rate related to the Company's right-of-use assets and lease liabilities as of June 30, 2023 are as follows: Weighted average remaining lease term (years): Finance leases 17.4 Operating leases 10.7 Weighted average discount rate: Finance leases 6.4 % Operating leases 4.3 %
Schedule of Cash Flow, Supplemental Disclosures	Supplemental information concerning the cash-flow impact arising from the Company's leases for the fiscal year ended June 30, 2023 recorded in the Company's unaudited consolidated statement of cash flows is detailed in the following table (in millions): Fiscal Year Ended Cash paid for amounts included in lease liabilities: Financing cash flows used for finance leases $ 19 Operating cash flows used for finance leases 15 Operating cash flows used for operating leases 16 Non-cash transactions: Right-of-use assets obtained in exchange for new finance lease liabilities 133 Right-of-use assets obtained in exchange for new operating lease liabilities $ 1
Schedule of Maturities of Lease Liabilities	As of June 30, 2023, the Company expects that its future minimum lease payments will become due and payable as follows: (Dollars in millions) Financing Leases Operating Leases Total 2024 $ 35 $ 13 $ 48 2025 34 10 44 2026 35 9 44 2027 35 9 44 2028 33 7 40 Thereafter 380 38 418 Total minimum lease payments 552 86 638 Less: interest 211 20 231 Total lease liabilities $ 341 $ 66 $ 407

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Net Revenue and Segment EBITDA	The following table includes Segment EBITDA for each of the Company's current reporting segments during the fiscal years ended June 30, 2023, 2022, and 2021: (Dollars in millions) Fiscal Year Ended June 30, 2023 2022 2021 Segment EBITDA reconciled to net (loss) earnings: Biologics $ 277 $ 777 $ 615 Pharma and Consumer Health 548 589 498 Subtotal $ 825 $ 1,366 $ 1,113 Reconciling items to net (loss) earnings Unallocated costs (1) (559) (286) 1 Depreciation and amortization (422) (378) (289) Interest expense, net (186) (123) (110) Income tax benefit (expense) 86 (80) (130) Net (loss) earnings $ (256) $ 499 $ 585 (1) Unallocated costs include restructuring and special items, stock-based compensation, gain (loss) on sale of subsidiary, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows: (Dollars in millions) Fiscal Year Ended June 30, 2023 2022 2021 Impairment charges and gain/loss on sale of assets (a) $ (98) $ (31) $ (9) Stock-based compensation (35) (54) (51) Restructuring and other special items (b) (98) (55) (31) Goodwill impairment charges (c) (210) — — Gain on sale of subsidiary (d) — 1 182 Other income (expense), net (e) 7 (28) (3) Non-allocated corporate costs, net (125) (119) (87) Total unallocated costs $ (559) $ (286) $ 1 (a) For the fiscal year ended June 30, 2023, impairment charges are primarily associated with an idle facility in the Biologics segment and obsolete equipment that could not be sold or repurposed in the Pharma and Consumer Health segment. In the three months ended June 30, 2023, the Company identified an indicator of impairment related to one of its facilities in the Biologics segment given the plans to pause any additional spend on site development due to a lack of demand, leading to a partial impairment charge of $54 million. The Company primarily utilized a market and income approach for real property and a cost approach for personal property to record the partial impairment on its idle facility. Impairment charges are recorded in Other operating expense in the consolidated statements of operations. Also, in the three months ended June 30, 2023, the Company identified an indicator of impairment related to obsolete equipment from a terminated project in the Pharma and Consumer Health segment, leading to a full impairment charge of $18 million. For the fiscal year ended June 30, 2022, impairment charges are primarily due to fixed asset impairment charges associated with dedicated equipment for a product the Company no longer manufactures in its Pharma and Consumer Health segment and obsolete equipment in its Biologics segment. (b) Restructuring and other special items for the fiscal year ended June 30, 2023 includes (i) restructuring charges associated with plans to reduce costs, consolidate facilities, and optimize our infrastructure across the organization and (ii) transaction and integration costs associated with the Metrics acquisition Restructuring and other special items for the fiscal year ended June 30, 2022 include (i) transaction and integration costs primarily associated with the Princeton, Bettera Wellness, Delphi, Hepatic, Acorda, and RheinCell transactions and (ii) unrealized losses on venture capital investments. Restructuring and other special items for the fiscal year ended June 30, 2021 include transaction and integration costs associated with the Anagni, Italy facility acquisition and the MaSTherCell Global, Inc., Skeletal, Delphi, and Acorda transactions, in addition to restructuring costs associated with the closure of the Company's Pharma and Consumer Health facility in Bolton, U.K. (c) The goodwill impairment charges for the fiscal year ended June 30, 2023 was associated with the Company’s Consumer Health reporting unit. For further details, see Note 4, Goodwill . (d) Gain on sale of subsidiary for the fiscal year ended June 30, 2022 was due to the sale of the Company’s facility and Blow-Fill-Seal business in Woodstock, Illinois. (e) Refer to Note 15, Other (income) expense, net for details of financing charges and foreign currency translation adjustments recorded within other (income) expense, net.	[1],[2],[3]
Total Assets for Each Segment and Reconciling in Consolidated Financial Statements	The following table includes total assets for each segment, as well as reconciling items necessary to total the amounts reported in the consolidated balance sheets. Total Assets (Dollars in millions) June 30, 2023 June 30, 2022 Biologics $ 5,746 $ 5,770 Pharma and Consumer Health 4,867 4,356 Corporate and eliminations 164 382 Total assets $ 10,777 $ 10,508
Capital Expenditures by Segment	Capital Expenditures Fiscal Year Ended June 30, (Dollars in millions) 2023 2022 2021 Biologics $ 346 $ 453 $ 516 Pharma and Consumer Health 214 183 151 Corporate 34 30 19 Total capital expenditures $ 594 $ 666 $ 686
Presentation of revenue and long-lived assets by geographic area	Long Lived Assets The following table presents long-lived assets—consisting of property, plant, and equipment, net of accumulated depreciation—by geographic area: (Dollars in millions) June 30, 2023 June 30, 2022 United States $ 2,758 $ 2,267 Europe 765 747 Other 159 113 Total $ 3,682 $ 3,127
[1] Restructuring and other special items for the fiscal year ended June 30, 2021 include transaction and integration costs associated with the Anagni, Italy facility acquisition and the MaSTherCell Global, Inc., Skeletal, Delphi, and Acorda transactions, in addition to restructuring costs associated with the closure of the Company's Pharma and Consumer Health facility in Bolton, U.K. Other (income) expense, net for details of financing charges and foreign currency translation adjustments recorded within other (income) expense, net.

Supplemental Balance Sheet In_2

Supplemental Balance Sheet Information (Tables)	12 Months Ended
	Jun. 30, 2023
Balance Sheet Related Disclosures [Abstract]
Work-in-Process and Finished Goods Inventories Include Raw Materials, Labor and Overhead	Work-in-process and inventories include raw materials, labor, and overhead. Total inventories consist of the following: (Dollars in millions) June 30, June 30, Raw materials and supplies $ 781 $ 651 Work-in-process 186 109 Total inventories, gross 967 760 Inventory cost adjustment (1) (190) (58) Total inventories $ 777 $ 702
Prepaid and Other Assets	Prepaid expenses and other current assets consist of the following: (Dollars in millions) June 30, June 30, Prepaid expenses $ 53 $ 61 Short-term contract assets 399 398 Spare parts supplies 24 22 Prepaid income tax 77 27 Non-U.S. value-added tax 38 48 Other current assets 42 70 Total prepaid expenses and other $ 633 $ 626
Property and Equipment	Property, plant, and equipment, net consist of the following: (Dollars in millions) June 30, June 30, Land, buildings, and improvements $ 1,887 $ 1,687 Machinery and equipment 2,287 1,891 Furniture and fixtures 61 48 Construction in progress 1,043 848 Property, plant, and equipment, at cost 5,278 4,474 Accumulated depreciation (1,596) (1,347) Property, plant, and equipment, net $ 3,682 $ 3,127
Other Assets Non Current	Other long-term assets consist of the following: (Dollars in millions) June 30, June 30, Operating lease right-of-use-assets $ 59 $ 93 Note receivable 53 51 Pension assets 18 37 Corporate-owned life insurance policies 41 35 Venture capital investments 36 33 Interest-rate swap 62 36 Long-term contract assets 18 43 Other 42 21 Total other long-term assets $ 329 $ 349
Other Accrued Liabilities	Other accrued liabilities consist of the following: (Dollars in millions) June 30, June 30, Contract liability $ 167 $ 211 Accrued employee-related expenses 160 198 Accrued expenses 134 140 Operating lease liabilities 11 14 Restructuring accrual 19 1 Accrued interest 35 32 Accrued income tax 44 50 Total other accrued liabilities $ 570 $ 646

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) - $ / shares shares in Millions	Jun. 15, 2020	Feb. 06, 2020	Jun. 30, 2023	Jun. 30, 2022
Stock Issued During Period, Shares, New Issues	8	8
Shares Issued, Price Per Share	$ 70.72	$ 58.58
Common stock, par value (usd per share)			$ 0.01	$ 0.01

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies Property and Equipment and Other Definite Lived Intangible Assets (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Depreciation expense	$ 286	$ 255	$ 196
Interest Costs Capitalized	24	15	17
Gain (Loss) on Sale of Assets and Asset Impairment Charges	$ (98)	$ (31)	$ (9)
Segment Reporting, Disclosure of Major Customers	10%		10%
Building And Improvements [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life	5 years
Building And Improvements [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life	50 years
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life	3 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life	10 years
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life	3 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life	7 years

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies Research and Development Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Research and Development Expense	$ 18	$ 23	$ 21
Concentration Risk trade receivables and current contract asset, Percentage	20%	14%
Segment Reporting, Disclosure of Major Customers	10%		10%

Basis of Presentation and Sum_6

Basis of Presentation and Summary of Significant Accounting Policies Recent Financial Accounting Standards (Details) $ in Millions	Jun. 30, 2023 USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating Lease, Liability	$ 66
Operating Lease, Liability, Statement of Financial Position [Extensible List]	Other Liabilities

Revenue Recognition Disaggregat

Revenue Recognition Disaggregation of Revenue by type of activity and reporting segment (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Line Items]
Net revenue	$ (4,263,000,000)	$ (4,802,000,000)	$ (3,998,000,000)
Greater Than One Year Member
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage to be recognized over the next six months		42%
Operating Segments
Disaggregation of Revenue [Line Items]
Net revenue	(4,263,000,000)	$ (4,802,000,000)	(3,998,000,000)
Operating Segments Excluding Intersegment Elimination
Disaggregation of Revenue [Line Items]
Net revenue	(4,265,000,000)	(4,805,000,000)	(4,001,000,000)
Biologics [Member] | Operating Segments
Disaggregation of Revenue [Line Items]
Net revenue	(1,978,000,000)	(2,534,000,000)	(1,938,000,000)
Biologics [Member] | Manufacturing & Commercial Product Supply [Member]
Disaggregation of Revenue [Line Items]
Net revenue	(450,000,000)	(608,000,000)	(532,000,000)
Biologics [Member] | Development Services [Member]
Disaggregation of Revenue [Line Items]
Net revenue	(1,528,000,000)	(1,926,000,000)	(1,406,000,000)
PharmaConsumerHealth | Operating Segments
Disaggregation of Revenue [Line Items]
Net revenue	(2,287,000,000)	(2,271,000,000)	(2,063,000,000)
PharmaConsumerHealth | Manufacturing & Commercial Product Supply [Member]
Disaggregation of Revenue [Line Items]
Net revenue	(1,452,000,000)	(1,474,000,000)	(1,321,000,000)
PharmaConsumerHealth | Development Services [Member]
Disaggregation of Revenue [Line Items]
Net revenue	(835,000,000)	(797,000,000)	(742,000,000)
Total Catalent before inter-segment revenue elimination [Member] | Manufacturing & Commercial Product Supply [Member]
Disaggregation of Revenue [Line Items]
Net revenue	(1,902,000,000)	(2,082,000,000)	(1,853,000,000)
Total Catalent before inter-segment revenue elimination [Member] | Development Services [Member]
Disaggregation of Revenue [Line Items]
Net revenue	(2,363,000,000)	(2,723,000,000)	(2,148,000,000)
Total Catalent Segment | Intersegment Eliminations
Disaggregation of Revenue [Line Items]
Net revenue	$ 2,000,000	$ 3,000,000	$ 3,000,000

Revenue Recognition Disaggreg_2

Revenue Recognition Disaggregation of Revenue by Geography (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Line Items]
Elimination of revenue attributable to multiple locations	$ (117)	$ (115)	$ (95)
Net revenue	4,263	4,802	3,998
Europe
Disaggregation of Revenue [Line Items]
Net revenue	1,257	1,506	1,343
International Other
Disaggregation of Revenue [Line Items]
Net revenue	355	327	288
United States [Member]
Disaggregation of Revenue [Line Items]
Net revenue	$ 2,768	$ 3,084	$ 2,462

Revenue Recognition Contractual

Revenue Recognition Contractual Liabilities (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Revenue Recognition and Deferred Revenue [Abstract]
Contract with Customer, Liability	$ 180	$ 220
Contract with Customer, Liability, Revenue Recognized	126
Revenue, Remaining Performance Obligation, Amount	$ 335

Revenue Recognition Contractu_2

Revenue Recognition Contractual Assets (Details) - USD ($) $ in Millions	Jun. 30, 2023	Jun. 30, 2022
Text Block [Abstract]
Contract with Customer, Asset	$ 417	$ 441

Revenue from Contract with Cu_2

Revenue from Contract with Customer (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Line Items]
Net revenue	$ 4,263,000,000	$ 4,802,000,000	$ 3,998,000,000
Development Services [Member] | Biologics [Member]
Disaggregation of Revenue [Line Items]
Net revenue	1,528,000,000	1,926,000,000	1,406,000,000
Development Services [Member] | PharmaConsumerHealth
Disaggregation of Revenue [Line Items]
Net revenue	835,000,000	797,000,000	742,000,000
Manufacturing & Commercial Product Supply [Member] | Biologics [Member]
Disaggregation of Revenue [Line Items]
Net revenue	450,000,000	608,000,000	532,000,000
Manufacturing & Commercial Product Supply [Member] | PharmaConsumerHealth
Disaggregation of Revenue [Line Items]
Net revenue	$ 1,452,000,000	$ 1,474,000,000	$ 1,321,000,000

Business Combinations Purchase

Business Combinations Purchase Agreement (Details) - USD ($)							1 Months Ended		12 Months Ended
	Oct. 01, 2022	Oct. 01, 2021	Aug. 01, 2021	Feb. 23, 2021	Feb. 11, 2021	Nov. 16, 2020	Apr. 30, 2022	Oct. 31, 2021	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Business Acquisition [Line Items]
Payment for acquisitions, net of cash acquired									$ (474,000,000)	$ (1,199,000,000)	$ (147,000,000)
Common stock, par value (usd per share)									$ 0.01	$ 0.01
Goodwill, Acquired During Period									$ 219,000,000	$ 572,000,000
Customer relationships [Member]
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life									13 years	13 years
Core technology [Member]
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life									11 years	11 years
3.500% Senior US Denominated Notes Member
Business Acquisition [Line Items]
Stated interest rate (percent)									350%
Skeletal Cell Therapy Support SA
Business Acquisition [Line Items]
Business Combination, Consideration Transferred						$ 15,000,000
Goodwill, Acquired During Period						$ 9,000,000
Hepatic Cell Therapy Support SA
Business Acquisition [Line Items]
Payment for acquisitions, net of cash acquired				$ (15,000,000)
Acorda Therapeutics, Inc
Business Acquisition [Line Items]
Business Combination, Consideration Transferred					$ 83,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment					79,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory					2,000,000
Goodwill, Acquired During Period					$ 2,000,000
Delphi Genetics SA
Business Acquisition [Line Items]
Business Combination, Consideration Transferred				50,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment				4,000,000
Goodwill, Acquired During Period				43,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt				6,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets				3,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles				7,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities				1,000,000
Bettera Holdings, LLC
Business Acquisition [Line Items]
Payment for acquisitions, net of cash acquired		$ (1,000,000,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment		72
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	$ 31
Goodwill, Acquired During Period								$ 531
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities		17
Bettera Holdings, LLC | Core technology [Member]
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	10 years
Bettera Holdings, LLC | Core Technology Bettera
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		$ 338
RheinCell Therapeutics
Business Acquisition [Line Items]
Payment for acquisitions, net of cash acquired			$ (26,000,000)
Goodwill, Acquired During Period			17,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			14,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities			$ 1,000,000
Princeton Cell Therapy
Business Acquisition [Line Items]
Payment for acquisitions, net of cash acquired							$ (45,000,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment							22,000,000
Goodwill, Acquired During Period							24,000,000
Vaccine Manufacturing and Innovation Centre
Business Acquisition [Line Items]
Payment for acquisitions, net of cash acquired							(134,000,000)
Business Acquisition, Transaction Costs							9,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment							165,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets							$ 1,000,000
Blow-Fill-Seal Business, Woodstock
Business Acquisition [Line Items]
Business Acquisition, Transaction Costs										$ 8,000,000
Goodwill, Acquired During Period									$ 54,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities										$ 2,000,000
Business Combination, Acquired Receivables, Description										$51 million
Metrics
Business Acquisition [Line Items]
Payment for acquisitions, net of cash acquired				$ (474,000,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	$ 195,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	5,000,000
Goodwill, Acquired During Period	219,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	52,000,000
Metrics | Customer relationships [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 52,000,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	12 years

Business Combinations Net Asset

Business Combinations Net Assets Acquired (Details) - USD ($)				1 Months Ended		12 Months Ended
	Oct. 01, 2022	Aug. 01, 2021	Feb. 23, 2021	Apr. 30, 2022	Oct. 31, 2021	Jun. 30, 2023	Jun. 30, 2022	Oct. 01, 2021	Mar. 31, 2021
Net Assets Acquired from Business Combinations
Goodwill, Acquired During Period						$ 219,000,000	$ 572,000,000
Notes Receivable Interest Rate						500%
Delphi Genetics SA
Net Assets Acquired from Business Combinations
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment			$ 4,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			7,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities			(1,000,000)
Goodwill, Acquired During Period			43,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets			$ 3,000,000
Bettera Holdings, LLC
Net Assets Acquired from Business Combinations
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment								$ 72
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	$ 31
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities								(17)
Goodwill, Acquired During Period					$ 531
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents								23
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables								16
RheinCell Therapeutics
Net Assets Acquired from Business Combinations
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		$ 14,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities		(4,000,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities		(1,000,000)
Goodwill, Acquired During Period		$ 17,000,000
Hepatic Cell Therapy Support SA
Net Assets Acquired from Business Combinations
Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt									$ 1,000,000
Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed									3,000,000
Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, PPE									$ 13,000,000
Princeton Cell Therapy
Net Assets Acquired from Business Combinations
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment				$ 22,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets				10,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities				(1,000,000)
Goodwill, Acquired During Period				24,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other				10,000,000
Vaccine Manufacturing and Innovation Centre
Net Assets Acquired from Business Combinations
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment				165,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities				(18,000,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets				1,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other				14,000,000
Business Acquisition, Transaction Costs				$ 9,000,000
Metrics
Net Assets Acquired from Business Combinations
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	195,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	5,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	52,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities	(12,000,000)
Goodwill, Acquired During Period	219,000,000
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net	474,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables	15,000,000
Customer relationships [Member]
Net Assets Acquired from Business Combinations
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life						13 years	13 years
Customer relationships [Member] | Metrics
Net Assets Acquired from Business Combinations
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 52,000,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	12 years
Product relationships [Member]
Net Assets Acquired from Business Combinations
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life						8 years	8 years
Core technology [Member]
Net Assets Acquired from Business Combinations
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life						11 years	11 years
Core technology [Member] | Bettera Holdings, LLC
Net Assets Acquired from Business Combinations
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	10 years
Core Technology Bettera | Bettera Holdings, LLC
Net Assets Acquired from Business Combinations
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles								338
Other Intangible Assets [Member]
Net Assets Acquired from Business Combinations
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life						5 years	4 years
Other Intangible Assets [Member] | Bettera Holdings, LLC
Net Assets Acquired from Business Combinations
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles								$ 361

Business Combinations, Divestit

Business Combinations, Divestitures (Details) - USD ($)				1 Months Ended		3 Months Ended	12 Months Ended
	Oct. 01, 2021	Feb. 23, 2021	Nov. 16, 2020	Apr. 30, 2022	Oct. 31, 2021	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021	Oct. 01, 2022
Business Acquisition [Line Items]
Goodwill, Acquired During Period							$ 219,000,000	$ 572,000,000
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal							0	1,000,000	$ 182,000,000
Payments to Acquire Businesses, Net of Cash Acquired							474,000,000	1,199,000,000	147,000,000
Blow-Fill-Seal Business, Woodstock
Business Acquisition [Line Items]
Proceeds from Divestiture of Businesses and Interests in Affiliates								300,000,000	300,000,000
Business Combination, Acquired Receivables, Gross Contractual Amount								50,000,000
Business Combination, Acquired Receivable, Fair Value									47,000,000
Disposal Group, Including Discontinued Operation, Assets							149,000,000
Goodwill, Acquired During Period							54,000,000
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal						$ 1	$ 182,000,000
Business Combination, Loan Discount								3,000,000
Business Acquisition, Transaction Costs								8,000,000
Business Combination, Working Capital Adjustments								6,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities								2,000,000
Proceeds From Divestiture Of Businesses, Net Cash Proceeds								284,000,000
Business Combination, Consideration Transferred, Other									16,000,000
Cash and Noncash Divestiture, Amount of Consideration Received								$ 331,000,000	$ 331,000,000
Business Combination, Acquired Receivables, Description								$51 million
Delphi Genetics SA
Business Acquisition [Line Items]
Goodwill, Acquired During Period		$ 43,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities		1,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		7,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment		4,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets		$ 3,000,000
Skeletal Cell Therapy Support SA
Business Acquisition [Line Items]
Goodwill, Acquired During Period			$ 9,000,000
Bettera Holdings, LLC
Business Acquisition [Line Items]
Goodwill, Acquired During Period					$ 531
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	$ 17
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables	16
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	72
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory										$ 31
Payments to Acquire Businesses, Net of Cash Acquired	$ 1,000,000,000
Vaccine Manufacturing and Innovation Centre
Business Acquisition [Line Items]
Business Acquisition, Transaction Costs				$ 9,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment				165,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets				1,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities				18,000,000
Payments to Acquire Businesses, Net of Cash Acquired				$ 134,000,000

Goodwill - Carrying Amount of G

Goodwill - Carrying Amount of Goodwill (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2020
Goodwill [Roll Forward]
Beginning balance	$ 3,039,000,000	$ 3,006,000,000	$ 2,519,000,000
Goodwill, Acquired During Period		219,000,000	572,000,000
Goodwill, Transfers		0
Foreign currency translation adjustments		24,000,000	(85,000,000)
Goodwill, Impairment Loss	(689)	(210,000,000)	0	$ 0
Ending balance		$ 3,039,000,000	$ 3,006,000,000
Goodwill Inputs Percentage, Discount Rate Minimum		900%
Goodwill Inputs Percentage, Discount Rate Maximum		1,050%
Goodwill Inputs Percentage, Long Term Revenue Growth Rate		300%
Time [Member]
Goodwill [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		1,008,747	1,055,511
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term		6 years 2 months 19 days	6 years 10 months 28 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term		5 years 2 months 23 days
Reported Value Measurement [Member]
Goodwill [Roll Forward]
Debt Instrument, Fair Value Disclosure		$ 4,888,000,000	$ 4,243,000,000
3.125% Senior US Denominated Notes
Goodwill [Roll Forward]
Stated interest rate (percent)		3.125%
3.125% Senior US Denominated Notes | Level 2 [Member] | Reported Value Measurement [Member]
Goodwill [Roll Forward]
Debt Instrument, Fair Value Disclosure		$ 550,000,000	550,000,000
3.500% Senior US Denominated Notes Member
Goodwill [Roll Forward]
Stated interest rate (percent)		350%
3.500% Senior US Denominated Notes Member | Level 2 [Member] | Reported Value Measurement [Member]
Goodwill [Roll Forward]
Debt Instrument, Fair Value Disclosure		$ 650,000,000	650,000,000
Softgel and Oral Technologies [Member]
Goodwill [Roll Forward]
Beginning balance	1,476,000,000	1,440,000,000	957,000,000
Goodwill, Acquired During Period		219,000,000	531,000,000
Goodwill, Transfers		15,000,000
Foreign currency translation adjustments		12,000,000	(48,000,000)
Ending balance		1,476,000,000	1,440,000,000
Biologics [Member]
Goodwill [Roll Forward]
Beginning balance	$ 1,563,000,000	1,566,000,000	1,562,000,000
Goodwill, Acquired During Period		0	41,000,000
Goodwill, Transfers		(15,000,000)
Foreign currency translation adjustments		12,000,000	(37,000,000)
Ending balance		1,563,000,000	$ 1,566,000,000
PharmaConsumerHealth
Goodwill [Roll Forward]
Goodwill, Impairment Loss		$ (210,000,000)

Definite Lived Long-Lived Ass_3

Definite Lived Long-Lived Assets - Other Intangible Assets Subject to Amortization (Detail) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Intangibles [Line Items]
Gross Carrying Value	$ 1,828	$ 1,763
Accumulated Amortization	(848)	(703)
Net Carrying Value	$ 980	$ 1,060
Core technology [Member]
Intangibles [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	11 years	11 years
Gross Carrying Value	$ 482	$ 480
Accumulated Amortization	(164)	(121)
Net Carrying Value	$ 318	$ 359
Customer relationships [Member]
Intangibles [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	13 years	13 years
Gross Carrying Value	$ 1,079	$ 1,020
Accumulated Amortization	(451)	(366)
Net Carrying Value	$ 628	$ 654
Product relationships [Member]
Intangibles [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	8 years	8 years
Gross Carrying Value	$ 243	$ 239
Accumulated Amortization	(216)	(204)
Net Carrying Value	$ 27	$ 35
Other Intangible Assets [Member]
Intangibles [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	5 years	4 years
Gross Carrying Value	$ 24	$ 24
Accumulated Amortization	(17)	(12)
Net Carrying Value	$ 7	$ 12

Definite Lived Long-Lived Ass_4

Definite Lived Long-Lived Assets - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Finite lived intangible assets disclosure [Abstract]
Amortization expense	$ 136	$ 123	$ 93

Definite Lived Long-Lived Ass_5

Definite Lived Long-Lived Assets - Future Amortization Expense (Detail) $ in Millions	Jun. 30, 2023 USD ($)
Finite lived intangible assets disclosure [Abstract]
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	$ 137
Finite-Lived Intangible Assets, Amortization Expense, Year Two	134
Finite-Lived Intangible Assets, Amortization Expense, Year Three	126
Finite-Lived Intangible Assets, Amortization Expense, Year Four	109
Finite-Lived Intangible Assets, Amortization Expense, Year Five	101
Finite-Lived Intangible Asset, Expected Amortization, after Year Five	373
Finite-Lived Intangible Asset, Expected Amortization. Total	$ 980

Restructuring and Other Costs_2

Restructuring and Other Costs (Details)	12 Months Ended
	Jun. 30, 2023 USD ($) employees	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Oct. 31, 2023 USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost				$ 25
Payments for Restructuring	$ 20,000,000
Facility exit and other costs	28,000,000	$ 1,000,000	$ 2,000,000
Restructuring Reserve	(19,000,000)	(1,000,000)
Restructuring and Related Cost, Incurred Cost	38,000,000	9,000,000	8,000,000
Restructuring, Settlement and Impairment Provisions	$ 66,000,000	10,000,000	10,000,000
Restructuring and Related Cost, Number of Positions Eliminated | employees	1,100
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]	Selling, general, and administrative expenses
Biologics [Member]
Restructuring Cost and Reserve [Line Items]
Employee-related reorganization	$ 41,000,000	1,000,000	0
PharmaConsumerHealth
Restructuring Cost and Reserve [Line Items]
Employee-related reorganization	8,000,000	5,000,000	9,000,000
Corporate and Eliminations [Member]
Restructuring Cost and Reserve [Line Items]
Employee-related reorganization	$ 17,000,000	$ 4,000,000	$ 1,000,000

Long-Term Obligations and Oth_2

Long-Term Obligations and Other Short-Term Borrowings - Additional Information (Detail) € in Millions	1 Months Ended	3 Months Ended	12 Months Ended
	Oct. 23, 2017 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 EUR (€)	Oct. 18, 2017
Schedule Of Debt [Line Items]
Debt, Current		$ 536,000,000	$ 536,000,000	$ 31,000,000
Long-term Debt and Finance Lease Obligations		4,313,000,000	4,313,000,000	4,171,000,000
Debt Instrument, Unused Borrowing Capacity, Amount		594,000,000	594,000,000
Letters of Credit Outstanding, Amount		6,000,000	6,000,000
Payments to Acquire Businesses, Gross	$ 950,000,000
Installment Payment for Acquisition, Next Twelve Months		50,000,000	50,000,000
Unamortized Debt Issuance Expense		39,000,000	39,000,000	42,000,000
Amortization of Debt Issuance Costs			8,000,000	7,000,000
Other Short-Term Borrowings		500,000,000	500,000,000
Sale and Leaseback Transaction, Gain (Loss), Net		24,000,000
Repayments of Lines of Credit		215,000,000
Line of Credit, Current		715,000,000	$ 715,000,000
Senior Secured Credit Facility [Member]
Schedule Of Debt [Line Items]
Pledge Percentage Of Capital Stock			100%
Pledge Percentage Of Equity Interest			100%
Maximum Percentage Of Voting Stock from non US subsidiary			65%
Revolving Credit Facility - Two [Member]
Schedule Of Debt [Line Items]
Debt and Capital Lease Obligations		500,000,000	$ 500,000,000
Revolving Credit Commitments [Member]
Schedule Of Debt [Line Items]
Debt and Capital Lease Obligations		$ 1,100,000,000	$ 1,100,000,000
Four Point Seven Five Percent Senior Euro Denominated Notes [Member]
Schedule Of Debt [Line Items]
Stated interest rate (percent)		4.75%	4.75%		4.75%
U.S. Dollar-denominated 4.875% Senior Notes [Member]
Schedule Of Debt [Line Items]
Stated interest rate (percent)						4.875%
U.S Dollar-denominated 5.00% Senior Notes [Member]
Schedule Of Debt [Line Items]
Debt and Capital Lease Obligations		$ 500,000,000	$ 500,000,000
Stated interest rate (percent)		5%	5%		5%
2.375% Senior Euro Denominated Notes [Member]
Schedule Of Debt [Line Items]
Debt and Capital Lease Obligations | €					€ 825
Stated interest rate (percent)		2.375%	2.375%		2.375%
Capital Lease Obligations [Member]
Schedule Of Debt [Line Items]
Debt and Capital Lease Obligations		$ 341,000,000	$ 341,000,000	234,000,000
Other Obligations [Member]
Schedule Of Debt [Line Items]
Debt and Capital Lease Obligations		$ 25,000,000	$ 25,000,000	2,000,000
3.125% Senior US Denominated Notes
Schedule Of Debt [Line Items]
Stated interest rate (percent)		3.125%	3.125%		3.125%
Term Loan Three Facility Dollar Denominated [Member]
Schedule Of Debt [Line Items]
Debt and Capital Lease Obligations		$ 1,418,000,000	$ 1,418,000,000	1,433,000,000
3.500% Senior US Denominated Notes Member
Schedule Of Debt [Line Items]
Debt and Capital Lease Obligations		$ 650	$ 650
Stated interest rate (percent)		350%	350%		350%
Accrued Liabilities [Member]
Schedule Of Debt [Line Items]
Payments to Acquire Businesses, Gross	$ 200,000,000
Reported Value Measurement [Member]
Schedule Of Debt [Line Items]
Debt and Capital Lease Obligations		$ 4,849,000,000	$ 4,849,000,000	4,202,000,000
Debt Instrument, Fair Value Disclosure		4,888,000,000	4,888,000,000	4,243,000,000
Reported Value Measurement [Member] | Debt Issuance Costs
Schedule Of Debt [Line Items]
Debt and Capital Lease Obligations		39,000,000	39,000,000	41,000,000
Level 2 [Member] | Reported Value Measurement [Member] | U.S Dollar-denominated 5.00% Senior Notes [Member]
Schedule Of Debt [Line Items]
Debt Instrument, Fair Value Disclosure		500,000,000	500,000,000	500,000,000
Level 2 [Member] | Reported Value Measurement [Member] | 2.375% Senior Euro Denominated Notes [Member]
Schedule Of Debt [Line Items]
Debt Instrument, Fair Value Disclosure		904,000,000	904,000,000	874,000,000
Level 2 [Member] | Reported Value Measurement [Member] | 3.125% Senior US Denominated Notes
Schedule Of Debt [Line Items]
Debt Instrument, Fair Value Disclosure		550,000,000	550,000,000	550,000,000
Level 2 [Member] | Reported Value Measurement [Member] | 3.500% Senior US Denominated Notes Member
Schedule Of Debt [Line Items]
Debt Instrument, Fair Value Disclosure		$ 650,000,000	$ 650,000,000	$ 650,000,000

Long-Term Obligations and Oth_3

Long-Term Obligations and Other Short-Term Borrowings- Maturities (Details)	Jun. 30, 2023 USD ($)
Long-term and Short-term Debt [Abstract]
Long-term Debt and Capital Lease Obligations, Repayments of Principal in Next Twelve Months	$ 536,000,000
Long Term Debt and Capital Lease Obligations Repayments of Principal in Year Two	48,000,000
Long Term Debt and Capital Lease Obligations Repayments of Principal in Year Three	31,000,000
Long Term Debt and Capital Lease Obligations Repayments of Principal in Year Four	32,000,000
Long Term Debt and Capital Lease Obligations Repayments of Principal in Year Five	1,429,000,000
Long Term Debt and Capital Lease Obligations Repayments of Principal After Year Five	2,812,000,000
Total	4,888,000,000
Line of Credit, Current	$ 715,000,000

Long-Term Obligations and Oth_4

Long-Term Obligations and Other Short-Term Borrowings Fair Value Measurements of Financial Instruments - Carrying Amounts and Estimated Fair Value of FInancial Instruments (Details) € in Millions	Jun. 30, 2023 USD ($)	Jun. 30, 2023 EUR (€)	Jun. 30, 2022 USD ($)
Reported Value Measurement [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure	$ 4,888,000,000		$ 4,243,000,000
Debt and Capital Lease Obligations	4,849,000,000		4,202,000,000
Estimate of Fair Value Measurement [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure	4,454,000,000		3,839,000,000
Debt and Capital Lease Obligations	4,454,000,000		3,839,000,000
U.S Dollar-denominated 5.00% Senior Notes [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt and Capital Lease Obligations	500,000,000
U.S Dollar-denominated 5.00% Senior Notes [Member] | Level 2 [Member] | Reported Value Measurement [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure	500,000,000		500,000,000
U.S Dollar-denominated 5.00% Senior Notes [Member] | Level 2 [Member] | Estimate of Fair Value Measurement [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure	482,000,000		483,000,000
2.375% Senior Euro Denominated Notes [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt and Capital Lease Obligations | €		€ 825
2.375% Senior Euro Denominated Notes [Member] | Level 2 [Member] | Reported Value Measurement [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure	904,000,000		874,000,000
2.375% Senior Euro Denominated Notes [Member] | Level 2 [Member] | Estimate of Fair Value Measurement [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure	784,000,000		744,000,000
3.125% Senior US Denominated Notes | Level 2 [Member] | Reported Value Measurement [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure	550,000,000		550,000,000
3.125% Senior US Denominated Notes | Level 2 [Member] | Estimate of Fair Value Measurement [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure	481,000,000		476,000,000
Senior Secured Credit Facilities & Other [Member] | Level 2 [Member] | Reported Value Measurement [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure	2,284,000,000		1,669,000,000
Senior Secured Credit Facilities & Other [Member] | Level 2 [Member] | Estimate of Fair Value Measurement [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure	2,141,000,000		1,575,000,000
Debt Issuance Costs | Reported Value Measurement [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt and Capital Lease Obligations	39,000,000		41,000,000
Debt Issuance Costs | Estimate of Fair Value Measurement [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt and Capital Lease Obligations	0		0
3.500% Senior US Denominated Notes Member
Fair Value Measurements Of Financial Instruments [Line Items]
Debt and Capital Lease Obligations	650
3.500% Senior US Denominated Notes Member | Level 2 [Member] | Reported Value Measurement [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure	650,000,000		650,000,000
3.500% Senior US Denominated Notes Member | Level 2 [Member] | Estimate of Fair Value Measurement [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure	$ 566,000,000
3.500% Senior US Denominated Notes | Level 2 [Member] | Reported Value Measurement [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure			650,000,000
3.500% Senior US Denominated Notes | Level 2 [Member] | Estimate of Fair Value Measurement [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure			$ 561,000,000

Long-Term Obligations and Oth_5

Long-Term Obligations and Other Short-Term Borrowings Interest Rate (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Debt Instrument [Line Items]
Long-term Debt and Capital Lease Obligations, Repayments of Principal in Next Twelve Months	$ 536,000,000
Long Term Debt and Capital Lease Obligations Repayments of Principal in Year Two	48,000,000
Long Term Debt and Capital Lease Obligations Repayments of Principal in Year Three	31,000,000
Long Term Debt and Capital Lease Obligations Repayments of Principal in Year Four	32,000,000
Long Term Debt and Capital Lease Obligations Repayments of Principal in Year Five	1,429,000,000
Long Term Debt and Capital Lease Obligations Repayments of Principal After Year Five	$ 2,812,000,000
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Incremental Term Loan | One Month
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	11.48%
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Incremental Term Loan | Three Month
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	26.161%
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Incremental Term Loan | Six Month
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	42.826%
Term Loan Three Facility Dollar Denominated [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations	$ 1,418,000,000	$ 1,433,000,000
Term Loan Three Facility Dollar Denominated [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	1.75%
Term Loan Three Facility Dollar Denominated [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	2.25%
Revolving Credit Facility - Two [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations	$ 500,000,000
Revolving Credit Commitments [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations	$ 1,100,000,000
Revolving Credit Commitments [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	0.75%
Revolving Credit Commitments [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	1.25%
Revolving Credit Commitments [Member] | Secured Overnight Financing Rate (SOFR)
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	10%

Earnings Per Share Calculations

Earnings Per Share Calculations of Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Earnings Per Share [Abstract]
Net earnings	$ (256)	$ 499	$ 585
Participating Securities, Distributed and Undistributed (Earnings) Loss, Basic	0	(16)	(56)
Net Income (Loss) Available to Common Stockholders, Basic	$ (256)	$ 483	$ 529
Weighted Average Number of Shares Outstanding, Basic	181,000,000	176,000,000	168,000,000
Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities	0	2,000,000	2,000,000
Weighted Average Number of Shares Outstanding, Diluted	181,000,000	178,000,000	170,000,000
Earnings Per Share, Basic	$ (1.42)	$ 2.74	$ 3.15
Earnings Per Share, Diluted	$ (1.42)	$ 2.73	$ 3.11
Text Block [Abstract]
Weighted Average Number of Shares Outstanding, Basic	181,000,000	176,000,000	168,000,000
Weighted Average Number of Shares Outstanding, Diluted	181,000,000	178,000,000	170,000,000

Earnings Per Share Earnings Per

Earnings Per Share Earnings Per Share - Additional Details (Details) - shares shares in Millions	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Series A Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	3	10

Derivative Instruments and He_3

Derivative Instruments and Hedging Activities - Additional Information (Detail) - USD ($)		9 Months Ended	12 Months Ended
	Nov. 23, 2020	Mar. 31, 2023	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021	May 17, 2019
Derivative [Line Items]
Derivatives used in Net Investment Hedge, Increase (Decrease), Gross of Tax			$ (30,000,000)	$ 121,000,000
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net			0	(11,000,000)
Net accumulated gain related to investment hedges			97,000,000
Derivative, Gain (Loss) on Derivative, Net			0	2,000,000	$ 17,000,000
Embedded Derivative, Estimate of Embedded Derivative Liability						$ 40,000,000
Cash Paid to Settle, Interest Rate Swap Agreement			2,000,000
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Purchases, Sales, Issues, Settlements	$ 4,000,000	$ 1
Federal			(1,000,000)	(8,000,000)	8,000,000
State and local			(1,000,000)	14,000,000	20,000,000
Non-U.S.			43,000,000	$ 66,000,000	$ 38,000,000
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax			$ 25
U.S. Denominated Term Loan [Member]
Derivative [Line Items]
Debt Instrument, Interest Rate, Effective Percentage			0.9431%		0.9985%
Total Debt, U.S Denominated Term Loan			$ 500,000,000

Fair Value Measures and Discl_3

Fair Value Measures and Disclosures (Details) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Marketable Securities		$ 89,000,000
Cash Surrender Value, Fair Value Disclosure		89,000,000
Interest Rate Cash Flow Hedge Asset at Fair Value	$ 62,000,000	36,000,000
Trading Securities at Fair Value	1,000,000	2,000,000
Level 1 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Marketable Securities	0
Premiums Receivable, Fair Value Disclosure		89,000,000
Interest Rate Cash Flow Hedge Asset at Fair Value	0	0
Trading Securities at Fair Value	1,000,000	2,000,000
Level 2 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Premiums Receivable, Fair Value Disclosure		0
Interest Rate Cash Flow Hedge Asset at Fair Value	62,000,000	36,000,000
Trading Securities at Fair Value	0
Level 3 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Premiums Receivable, Fair Value Disclosure		0
Interest Rate Cash Flow Hedge Asset at Fair Value	0
Trading Securities at Fair Value	$ 0	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Jun. 30, 2023	Sep. 30, 2023	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Income Tax Contingency [Line Items]
Undistributed Earnings of Foreign Subsidiaries	$ 421,000,000
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	7
Deferred Tax Assets, Valuation Allowance	159,000,000	$ 53,000,000	$ 149,000,000
Unrecognized Tax Benefits	4,000,000		5,000,000	$ 5,000,000	$ 4,000,000
Unrecognized Tax Benefits, Interest on Income Taxes Accrued	0		$ 1,000,000
Domestic Tax Authority [Member]
Income Tax Contingency [Line Items]
Operating Loss Carryforwards	609,000,000
Operating Loss Carryforwards, Subject to Limitations, Section 382	286,000,000
Operating Loss Carryforwards, Indefinite Life	564,000,000
State and Local Jurisdiction [Member]
Income Tax Contingency [Line Items]
Operating Loss Carryforwards	$ 378,000,000
Operating Loss Carryforwards, Carry Forward Period	20 years
Deferred Tax Assets, Valuation Allowance	$ 23,000,000
Foreign Tax Authority [Member]
Income Tax Contingency [Line Items]
Operating Loss Carryforwards	$ 319,000,000
Operating Loss Carryforwards, Carry Forward Period	3 years

Income Taxes Schedule of Income

Income Taxes Schedule of Income before Tax Domestic and Foreign (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Income Tax Disclosure [Abstract]
U.S. operations	$ (410,000,000)	$ 224,000,000	$ 457,000,000
Non-U.S. operations	68,000,000	355,000,000	258,000,000
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$ (342,000,000)	$ 579,000,000	$ 715,000,000

Income Taxes-Components of Inco

Income Taxes-Components of Income Tax Expense (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Current Income Tax Expense (Benefit), Continuing Operations [Abstract]
Federal	$ (1,000,000)	$ (8,000,000)	$ 8,000,000
State and local	(1,000,000)	14,000,000	20,000,000
Non-U.S.	43,000,000	66,000,000	38,000,000
Total current	41,000,000	72,000,000	66,000,000
Deferred:
Federal	(99,000,000)	6,000,000	62,000,000
State and local	(4,000,000)	(5,000,000)	7,000,000
Non-U.S.	(24,000,000)	7,000,000	(5,000,000)
Total deferred	(127,000,000)	8,000,000	64,000,000
Total provision	$ (86,000,000)	$ 80,000,000	$ 130,000,000

Income Taxes-Income Tax Reconci

Income Taxes-Income Tax Reconciliation (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Provision at U.S. federal statutory tax rate	$ (72,000,000)	$ 122,000,000	$ 150,000,000
State and local income taxes	(13,000,000)	10,000,000	26,000,000
Foreign tax rate differential	(5,000,000)	(28,000,000)	(14,000,000)
Effective Income Tax Rate Reconciliation, Global intangible low tax income	2,000,000	6,000,000	3,000,000
Permanent items	13,000,000	2,000,000	(5,000,000)
Unrecognized tax positions	(1,000,000)	1,000,000	3,000,000
Tax valuation allowance	5,000,000	94,000,000	(7,000,000)
Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount	30,000,000	43,000,000	24,000,000
Withholding Tax and other foreign taxes	1,000,000	1,000,000	1,000,000
Change in tax rate	18,000,000	1,000,000	2,000,000
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount	(3,000,000)	(2,000,000)	(5,000,000)
Effective Tax Reconciliation, Benefit from Swiss Tax Reform	0	83,000,000	0
Other	(1,000,000)	(1,000,000)	0
Total provision	(86,000,000)	$ 80,000,000	$ 130,000,000
Effective Tax Reconciliation, Net Benefit from Swiss Tax Reform	$ 21

Income Taxes-Deferred Tax Asset

Income Taxes-Deferred Tax Assets (Details) - USD ($)	Sep. 30, 2023	Jun. 30, 2023	Jun. 30, 2022
Deferred income tax assets:
Accrued liabilities		$ 57,000,000	$ 33,000,000
Equity compensation		13,000,000	14,000,000
Loss and tax credit carryforwards		287,000,000	230,000,000
Foreign currency		3,000,000	19,000,000
Pension		19,000,000	17,000,000
Property-related		50,000,000	14,000,000
Intangibles		0	1,000,000
Deferred Income Tax, Operating Lease, Liabilities		(38,000,000)	(39,000,000)
Euro Denominated Debt		1,000,000	0
Other		1,000,000	2,000,000
Total deferred income tax assets		469,000,000	369,000,000
Valuation allowance	$ (53,000,000)	(159,000,000)	(149,000,000)
Deferred Tax Assets, Net of Valuation Allowance		310,000,000	220,000,000
Deferred income tax liabilities:
Foreign currency		0	(6,000,000)
Property-related		(247,000,000)	(227,000,000)
Goodwill and other intangibles		(71,000,000)	(113,000,000)
Deferred Income Tax, Right-of-Use Asset		(13,000,000)	(21,000,000)
Other		0	(1,000,000)
Total deferred income tax liabilities		(331,000,000)	(368,000,000)
Deferred Tax Liabilities, Net		$ 21,000,000	$ 148,000,000

Income Taxes-Balance Sheet (Det

Income Taxes-Balance Sheet (Details) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Non-current deferred tax asset	$ 55,000,000	$ 49,000,000
Non-current deferred tax liability	76,000,000	197,000,000
Deferred Tax Liabilities, Net	$ (21,000,000)	(148,000,000)
Marketable Securities		$ 89,000,000

Income Taxes-Unrecognized Tax B

Income Taxes-Unrecognized Tax Benefits (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Reconciliation of Unrecognized Tax Benefits [Roll Forward]
Beginning Balance	$ 5,000,000	$ 5,000,000	$ 4,000,000
Additions based on tax positions related to the current year		1,000,000
Additions for tax positions of prior years	2,000,000	1,000,000	3,000,000
Reductions for tax positions of prior years	(1,000,000)
Settlements	(1,000,000)	(1,000,000)
Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations	(1,000,000)	(1,000,000)	(2,000,000)
Ending Balance	$ 4,000,000	$ 5,000,000	$ 5,000,000

Employee Retirement Benefit P_3

Employee Retirement Benefit Plans-Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Multiemployer Plans, Estimated Annual Cash Contribution	$ 2
Eberbach Pension Promissory Note or Loan [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Stated interest rate (percent)	5%
Retirement Benefits [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Multiemployer Plan, Pension, Significant, Future Employer Contribution, Amount	$ 38
Actual Asset Allocation (percent)	100%	100%
Target Asset Allocation (percent)	100%	100%
Actual Asset Allocation	$ 202	$ 240
Retirement Benefits [Member] | Equity Securities [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Actual Asset Allocation (percent)	2.90%	4.10%
Target Asset Allocation (percent)	2.90%	4.10%
Actual Asset Allocation	$ 6	$ 10
Retirement Benefits [Member] | Cash [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Actual Asset Allocation (percent)	4.50%
Target Asset Allocation (percent)	4.50%
Actual Asset Allocation	$ 9

Employee Retirement Benefit P_4

Employee Retirement Benefit Plans-Accumulated Benefit Obligation (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Employer contributions between measurement date and reporting date
Fair value of plan assets at beginning of year	$ 240
Fair value of plan assets at end of year	202	$ 240
Retirement Benefits [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Amortization of Gain (Loss)	(1)	(2)
Accumulated Benefit Obligation	242	262
Change in Benefit Obligation
Benefit obligation at beginning of year	268	372
Company service cost	3	4
Interest cost	9	5
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant	1	0
Settlements	(4)	(1)
Defined Benefit Plan, Benefit Obligation, Benefits Paid	10	9
Actuarial (gain)/loss	(28)	(71)
Exchange rate gain/(loss)	7	(32)
Benefit obligation at end of year	246	268
Employer contributions between measurement date and reporting date
Fair value of plan assets at beginning of year	240	318
Actual return on plan assets	(38)	(50)
Company contributions	7	10
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant	1	0
Settlements	(4)	(1)
Defined Benefit Plan, Plan Assets, Benefits Paid	(10)	(9)
Exchange rate gain/(loss)	6	(28)
Fair value of plan assets at end of year	202	240
Funded status at end of year	(44)	(28)
Net Pension assets (liabilities)	(44)	(28)
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant	1	0
Other Post-Retirement Benefits [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Amortization of Gain (Loss)	0	0
Accumulated Benefit Obligation	2	2
Change in Benefit Obligation
Benefit obligation at beginning of year	2
Company service cost	0	0
Interest cost	0	0
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant	0	0
Settlements	0	0
Defined Benefit Plan, Benefit Obligation, Benefits Paid	0	0
Actuarial (gain)/loss	0	0
Exchange rate gain/(loss)	0	0
Benefit obligation at end of year	2	2
Employer contributions between measurement date and reporting date
Fair value of plan assets at beginning of year	0
Actual return on plan assets	0	0
Company contributions	0	0
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant	0	0
Settlements	0	0
Defined Benefit Plan, Plan Assets, Benefits Paid	0	0
Exchange rate gain/(loss)	0	0
Fair value of plan assets at end of year	0	0
Funded status at end of year	(2)	(2)
Net Pension assets (liabilities)	(2)	(2)
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant	$ 0	$ 0

Employee Retirement Benefit P_5

Employee Retirement Benefit Plans-Balance Sheet (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]	Pension liability	Pension liability
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Expected Return (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Pension liability	Pension liability
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Amortization of Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Pension liability	Pension liability
Retirement Benefits [Member]
Amounts Recognized in Statement of Financial Position
Noncurrent assets	$ 18	$ 37
Current liabilities	(1)	(1)
Noncurrent liabilities	(61)	(64)
Funded status at end of year	(44)	(28)
Amounts Recognized in Accumulated Other Comprehensive Income
Prior service cost	(1)	(1)
Net (gain)/loss	66	49
Total accumulated other comprehensive income at the end of the year	65	48
Additional Information for Plan with ABO in Excess of Plan Assets
Projected benefit obligation	129	132
Accumulated benefit obligation	126	128
Fair value of plan assets	68	67
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]
Service cost	3	4
Interest cost	9	5
Defined Benefit Plan, Expected Return (Loss) on Plan Assets	9	10
Defined Benefit Plan, Amortization of Gain (Loss)	(1)	(2)
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment	1
Net periodic benefit cost	5	1
Other Post-Retirement Benefits [Member]
Amounts Recognized in Statement of Financial Position
Noncurrent assets	0	0
Current liabilities	0	0
Noncurrent liabilities	(2)	(2)
Funded status at end of year	(2)	(2)
Amounts Recognized in Accumulated Other Comprehensive Income
Prior service cost	0	0
Net (gain)/loss	(1)	(1)
Total accumulated other comprehensive income at the end of the year	(1)	(1)
Additional Information for Plan with ABO in Excess of Plan Assets
Projected benefit obligation	2	2
Accumulated benefit obligation	2	2
Fair value of plan assets	0	0
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]
Service cost	0	0
Interest cost	0	0
Defined Benefit Plan, Expected Return (Loss) on Plan Assets	0	0
Defined Benefit Plan, Amortization of Gain (Loss)	0	0
Net periodic benefit cost	$ 0	$ 0

Employee Retirement Benefit P_6

Employee Retirement Benefit Plans-AOCI (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]
Net (gain)/loss arising during the year	$ 17	$ (13)	$ 0
Retirement Benefits [Member]
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]
Net (gain)/loss arising during the year	17	(14)
Exchange rate gain/(loss) recognized during the year	0	1
Total minimum pension liability, pretax	17	(13)
Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Tax	22	(12)
Estimated Amounts to be Amortized from Accumulated Other Comprehensive Income into Net Periodic Benefit Cost
Net (gain)/loss	$ 2	$ 1
Financial Assumptions Used to Determine Benefit Obligations at the Balance Sheet Date
Discount rate (percent)	4.30%	3.60%
Rate of compensation increases (percent)	2.70%	2.70%
Financial Assumptions Used to Determine Net Periodic Benefit Cost for Financial Year
Discount rate (percent)	3.60%	1.60%
Rate of compensation increases (percent)	2.70%	2%
Expected long-term rate of return (percent)	3.90%	3.40%
Expected Future Contributions
Fiscal Year 2020 Expected Future Contributions	$ 8	$ 7
Other Post-Retirement Benefits [Member]
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]
Net (gain)/loss arising during the year	0	0
Exchange rate gain/(loss) recognized during the year	0	0
Total minimum pension liability, pretax	0	0
Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Tax	0	0
Estimated Amounts to be Amortized from Accumulated Other Comprehensive Income into Net Periodic Benefit Cost
Net (gain)/loss	$ 0	$ 0
Financial Assumptions Used to Determine Benefit Obligations at the Balance Sheet Date
Discount rate (percent)	4.70%	4%
Financial Assumptions Used to Determine Net Periodic Benefit Cost for Financial Year
Discount rate (percent)	4%	2%
Expected Future Contributions
Fiscal Year 2020 Expected Future Contributions	$ 0	$ 0

Employee Retirement Benefit P_7

Employee Retirement Benefit Plans-Fiscal Year Maturity (Details) - USD ($) $ in Millions	Jun. 30, 2023	Jun. 30, 2022
Retirement Benefits [Member]
Expected Future Benefit Payments
Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months	$ 14	$ 14
Defined Benefit Plan, Expected Future Benefit Payment, Year Two	15	13
Defined Benefit Plan, Expected Future Benefit Payment, Year Three	16	14
Defined Benefit Plan, Expected Future Benefit Payment, Year Four	15	16
Defined Benefit Plan, Expected Future Benefit Payment, Year Five	15	14
Defined Benefit Plan, Expected Future Benefit Payment, Five Fiscal Years Thereafter	$ 84	$ 80
Actual Asset Allocation (percent)	100%	100%
Actual Asset Allocation	$ 202	$ 240
Target Asset Allocation (percent)	100%	100%
Retirement Benefits [Member] | Equity Securities [Member]
Expected Future Benefit Payments
Actual Asset Allocation (percent)	2.90%	4.10%
Actual Asset Allocation	$ 6	$ 10
Target Asset Allocation (percent)	2.90%	4.10%
Retirement Benefits [Member] | US Government Agencies Debt Securities [Member]
Expected Future Benefit Payments
Actual Asset Allocation (percent)	36.80%	35.60%
Actual Asset Allocation	$ 74	$ 85
Target Asset Allocation (percent)	36.80%	35.60%
Retirement Benefits [Member] | Corporate Debt Securities [Member]
Expected Future Benefit Payments
Actual Asset Allocation (percent)	16.20%	18.30%
Actual Asset Allocation	$ 33	$ 44
Target Asset Allocation (percent)	16.20%	18.30%
Retirement Benefits [Member] | Real Estate [Member]
Expected Future Benefit Payments
Actual Asset Allocation (percent)	3.30%	4.90%
Actual Asset Allocation	$ 7	$ 12
Target Asset Allocation (percent)	3.30%	4.90%
Retirement Benefits [Member] | Insurance Contracts [Member]
Expected Future Benefit Payments
Actual Asset Allocation (percent)	14.90%	12%
Actual Asset Allocation	$ 30	$ 29
Target Asset Allocation (percent)	14.90%	12%
Retirement Benefits [Member] | Other Assets [Member]
Expected Future Benefit Payments
Actual Asset Allocation (percent)	21.40%	25.10%
Actual Asset Allocation	$ 43	$ 60
Target Asset Allocation (percent)	21.40%	25.10%
Other Post-Retirement Benefits [Member]
Expected Future Benefit Payments
Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months	$ 0	$ 0
Defined Benefit Plan, Expected Future Benefit Payment, Year Two	0	0
Defined Benefit Plan, Expected Future Benefit Payment, Year Three	0	0
Defined Benefit Plan, Expected Future Benefit Payment, Year Four	0	0
Defined Benefit Plan, Expected Future Benefit Payment, Year Five	0	0
Defined Benefit Plan, Expected Future Benefit Payment, Five Fiscal Years Thereafter	$ 1	$ 1
Actual Asset Allocation (percent)	0%	0%
Actual Asset Allocation	$ 0	$ 0
Target Asset Allocation (percent)	0%	0%
Other Post-Retirement Benefits [Member] | Equity Securities [Member]
Expected Future Benefit Payments
Actual Asset Allocation (percent)	0%	0%
Actual Asset Allocation	$ 0	$ 0
Target Asset Allocation (percent)	0%	0%
Other Post-Retirement Benefits [Member] | US Government Agencies Debt Securities [Member]
Expected Future Benefit Payments
Actual Asset Allocation (percent)	0%	0%
Actual Asset Allocation	$ 0	$ 0
Target Asset Allocation (percent)	0%	0%
Other Post-Retirement Benefits [Member] | Corporate Debt Securities [Member]
Expected Future Benefit Payments
Actual Asset Allocation (percent)	0%	0%
Actual Asset Allocation	$ 0	$ 0
Target Asset Allocation (percent)	0%	0%
Other Post-Retirement Benefits [Member] | Real Estate [Member]
Expected Future Benefit Payments
Actual Asset Allocation (percent)	0%	0%
Actual Asset Allocation	$ 0	$ 0
Target Asset Allocation (percent)	0%	0%
Other Post-Retirement Benefits [Member] | Insurance Contracts [Member]
Expected Future Benefit Payments
Actual Asset Allocation (percent)	0%	0%
Actual Asset Allocation	$ 0	$ 0
Target Asset Allocation (percent)	0%	0%
Other Post-Retirement Benefits [Member] | Other Assets [Member]
Expected Future Benefit Payments
Actual Asset Allocation (percent)	0%	0%
Actual Asset Allocation	$ 0	$ 0
Target Asset Allocation (percent)	0%	0%

Employee Retirement Benefit P_8

Employee Retirement Benefit Plans-Fair Value (Details) - USD ($) $ in Millions	Jun. 30, 2023	Jun. 30, 2022
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 202	$ 240
Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	175	213
Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	27	27
Fair Value Measured at Net Asset Value
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	6	10
Equity Securities [Member] | Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities [Member] | Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	6	10
Equity Securities [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities [Member] | Fair Value Measured at Net Asset Value
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Debt Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	107	129
Debt Securities [Member] | Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Debt Securities [Member] | Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	107	129
Debt Securities [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Debt Securities [Member] | Fair Value Measured at Net Asset Value
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Real Estate [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	7	12
Real Estate [Member] | Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Real Estate [Member] | Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	5	10
Real Estate [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2	2
Real Estate [Member] | Fair Value Measured at Net Asset Value
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Assets [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	82	89
Other Assets [Member] | Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Assets [Member] | Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	57	64
Other Assets [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	25	25
Other Assets [Member] | Fair Value Measured at Net Asset Value
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Hedge Funds [Member] | Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 20	$ 35

Employee Retirement Benefit P_9

Employee Retirement Benefit Plans-Level 3 (Details) - Level 3 [Member] $ in Millions	12 Months Ended
	Jun. 30, 2023 USD ($)
Employer contributions between measurement date and reporting date
Beginning balance	$ 27
Relating to assets still held at the reporting date	2
Purchases, sales, settlements, contributions and benefits paid	(3)
Transfers in and/or out of Level 3	1
Ending balance	27
Insurance Contracts [Member]
Employer contributions between measurement date and reporting date
Beginning balance	9
Relating to assets still held at the reporting date	0
Purchases, sales, settlements, contributions and benefits paid	(1)
Transfers in and/or out of Level 3	0
Ending balance	8
Other Unobservable Assets [Member]
Employer contributions between measurement date and reporting date
Beginning balance	18
Relating to assets still held at the reporting date	2
Purchases, sales, settlements, contributions and benefits paid	(2)
Transfers in and/or out of Level 3	1
Ending balance	$ 19

Employee Retirement Benefit _10

Employee Retirement Benefit Plans-Assumed Healthcare Trend Rates (Details) - Other Post-Retirement Benefits [Member] - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Effect of 1% Change in Healthcare Cost Trend Rate
Fiscal Year 2020 Expected Future Contributions	$ 0	$ 0
Discount rate (percent)	4.70%	4%
Discount rate (percent)	4%	2%
Post 65 [Member]
Assumed Healthcare Cost Trend Rates at the Balance Sheet Date
Healthcare cost trend rate-initial (percent)	4.80%	4.60%
Healthcare cost trend rate-ulitimate (percent)	4.10%	4.10%
Year in which ultimate rates are reached	2040	2040

Equity and Accumulated Other _2

Equity and Accumulated Other Comprehensive Income (Loss) Equity (Details) $ / shares in Units, number in Millions					3 Months Ended	9 Months Ended	12 Months Ended
	Nov. 18, 2021 USD ($) shares	Nov. 23, 2020 USD ($) shares	Jun. 15, 2020 USD ($) $ / shares shares	Feb. 06, 2020 USD ($) $ / shares shares	Mar. 31, 2023 USD ($)	Mar. 31, 2023 USD ($)	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2021 USD ($) $ / shares shares	Jun. 30, 2023 USD ($) $ / shares shares	May 17, 2019 USD ($)
Equity [Abstract]
Common Stock, Shares Authorized | shares							1,000,000,000		1,000,000,000
Common stock, par value (usd per share) | $ / shares							$ 0.01		$ 0.01
Preferred Stock, Shares Authorized | shares							100,000,000		100,000,000
Preferred Stock, Shares Issued & Outstanding | shares							0		0
Preferred Stock, Par or Stated Value Per Share | $ / shares							$ 0.01	$ 0.01	$ 0.01
Stock Issued During Period, Shares, New Issues | shares			8,000,000	8,000,000
Shares Issued, Price Per Share | $ / shares			$ 70.72	$ 58.58
Stock Issued During Period, Value, New Issues | $			$ 548,000,000	$ 494,000,000				$ 82,000,000
Net Proceeds used to Repay Debt, Stock Issued During Period, New Issues | $			$ 200,000,000	$ 100,000,000
Stcok Issued During Period, Shares, Over-allotment Option			1
Stock Issued During Period, Value, Over-allotment Option | $			$ 82,000,000
Auction Market Preferred Securities, Stock Series [Line Items]
Preferred Stock, Shares Authorized | shares							100,000,000		100,000,000
Preferred Stock, Par or Stated Value Per Share | $ / shares							$ 0.01	$ 0.01	$ 0.01
Preferred Stock, Shares Issued | shares							0	650,000	0
Preferred Stock, Issuance Value | $								$ 650,000,000
Preferred Stock, Value, Issued | $								1,000
Preferred Stock, Issuance Value, Net | $									$ 646,000,000
Embedded Derivative, Estimate of Embedded Derivative Liability | $										$ 40,000,000
Conversion of Stock, Shares Converted | shares	384,777	265,223
Dividends, Preferred Stock, Stock | $	$ 2	$ 2,000,000
Convertible Preferred Stock, Shares Issued upon Conversion | shares	20.32	20.33
Stock Issued During Period, Shares, Conversion of Convertible Securities | shares	7,817,554	5,392,280
Preferred Stock, Shares Issued & Outstanding | shares							0		0
Stock Issued During Period, Value, Conversion of Convertible Securities | $							$ 362,000,000	253,000,000
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Purchases, Sales, Issues, Settlements | $		$ 4,000,000				$ 1
Additional Paid-in Capital [Member]
Equity [Abstract]
Stock Issued During Period, Value, New Issues | $								82,000,000
Auction Market Preferred Securities, Stock Series [Line Items]
Stock Issued During Period, Value, Conversion of Convertible Securities | $		$ 253,000,000			$ 362		$ 362,000,000	$ 253,000,000
Designated shares [Member]
Equity [Abstract]
Preferred Stock, Shares Authorized | shares								1,000,000
Auction Market Preferred Securities, Stock Series [Line Items]
Preferred Stock, Shares Authorized | shares								1,000,000

Equity and Accumulated Other _3

Equity and Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Earnings/(Loss) (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Net of Tax	$ (354,000,000)	$ (394,000,000)	$ (317,000,000)	$ (386,000,000)
Other comprehensive income /(loss), net of tax	40,000,000	(77,000,000)	69,000,000
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax		(9,000,000)	0
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	32,000,000	(110,000,000)	67,000,000
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax		(3,000,000)	(1,000,000)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	34,000,000	(78,000,000)	69,000,000
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	6,000,000	1,000,000
Accumulated Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Net of Tax	(346,000,000)	(378,000,000)	(268,000,000)	(335,000,000)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax		(110,000,000)	67,000,000
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax		0
Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Net of Tax	(52,000,000)	(38,000,000)	(47,000,000)	(47,000,000)
Other Comprehensive Income (Loss), before Reclassifications, before Tax	(14,000,000)
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax	14,000,000
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	(16,000,000)	8,000,000	0
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	2,000,000	1,000,000
AOCI, Derivative Qualifying as Hedge, Excluded Component, Parent
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Net of Tax	45,000,000	27,000,000	0	(3,000,000)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax		27,000,000	3,000,000
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax		0
ACOI, Accumulated Gain (Loss), Marketable Securities
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Net of Tax	0	(4,000,000)	(1,000,000)	0
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax	4,000,000	(3,000,000)	(1,000,000)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax		(3,000,000)	(1,000,000)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	4,000,000	0
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Net of Tax	(1,000,000)	(1,000,000)	(1,000,000)	$ (1,000,000)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	$ 0	0	$ 0
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax		$ 0

Equity and Accumulated Other _4

Equity and Accumulated Other Comprehensive Income (Loss)-Minimum Pension Liability (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Equity [Abstract]
Net investment hedge	$ (30)	$ 121	$ (56)
Long term inter-company loans	12	(37)	39
Translation adjustments	43	(169)	72
Total foreign currency translation adjustments, pretax	25	(85)	55
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax	(7)	25	(12)
Total foreign currency translation adjustments, net of tax		(110)	67
Net Derivative and Hedge (gain)/loss arising during the year	25	36	4
Derivative and Hedge, (Income) Loss	7	9	1
Other Comprehensive Income, Debt Securities, Derivative and Hedge, Gain (Loss), after Adjustment and Tax	(18)	27	3
Net gain/(loss) arising during the year	(17)	13	0
Pension liability tax	(3)	4	0
Net change in minimum pension liability, net of tax		9	0
Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, before Tax	5	(3)	(1)
Other Comprehensive Income (Loss), Securities, Available-for-sale, Tax	$ (1)	0	0
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax		$ (3)	$ (1)

Equity (Details)

Equity (Details) - USD ($)	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020	Jun. 15, 2020	Feb. 06, 2020	May 17, 2019
Redeemable Preferred Stock [Line Items]
Preferred Stock, Shares Authorized	100,000,000	100,000,000
Preferred Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01	$ 0.01
Preferred Stock, Shares Issued	0	0	650,000
Preferred Stock, Issuance Value			$ 650,000,000
Preferred Stock, Value, Issued			1,000
Shares Issued, Price Per Share					$ 70.72	$ 58.58
Preferred Stock, Value, Outstanding	$ 0	$ 0
Preferred Stock, Issuance Value, Net	646,000,000
Embedded Derivative, Estimate of Embedded Derivative Liability							$ 40,000,000
Redeemable Preferred Stock Outstandings	$ 0	$ 0	$ 359,000,000	$ 607,000,000
Designated shares [Member]
Redeemable Preferred Stock [Line Items]
Preferred Stock, Shares Authorized			1,000,000

Equity Based Compensation (Addi

Equity Based Compensation (Additional) (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	15,600,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Number of Shares, Period Increase (Decrease)	2.25
Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price	$ 37.14	$ 32.07	$ 24.36
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	$ 3,000,000	$ 29,000,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 7 months 6 days
Weighted Average Grant Date Fair Value of Restricted Stock Unit	$ 76,000,000	57,000,000
Stock Option Granted Contractual Term	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	$ 35,000,000	54,000,000	$ 51,000,000
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years
Weighted Average Grant Date Fair Value of Restricted Stock Unit	$ 75.62	109.63	94.19
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	$ 39,000,000	$ 33,000,000	$ 39,000,000
Employee Stock Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	37%	37%	27%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	3.20%	0.70%	0.30%
Employee Stock Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	4 years 3 months 18 days	3 years 8 months 12 days	6 years 3 months
Share Based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions, Expected Dividend Payments, Per Share	$ 0	$ 0	$ 0
Performance Shares [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	41%	39%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	2 years 4 months 24 days	2 years 4 months 24 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	3%	0.30%
Performance Shares [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	47%	41%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	2 years 10 months 24 days	2 years 10 months 24 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	4.60%	1.50%
Share Based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions, Expected Dividend Payments, Per Share	$ 0	$ 0
Stock Compensation Plan - Omnibus [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	151,000	183,000	231,000

Equity Based Compensation (Opti

Equity Based Compensation (Option Activity) (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price	$ 71.19	$ 63.74
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	104.84
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	35.17
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price	94.34
Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price	67.37
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	71.19
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price	$ 54.62
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	$ 3,000,000	$ 29,000,000
Payments Related to Tax Withholding for Share-based Compensation	0	10,000,000	$ 46,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	9,000,000	$ 6,000,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 2,000,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 7 months 6 days
Time [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,008,747	1,055,511
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	151,454
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	(114,922)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	(62,729)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period	(20,567)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	1,008,747
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	596,627
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	6 years 2 months 19 days	6 years 10 months 28 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term	5 years 2 months 23 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	$ 2,225,819	$ 47,013,454
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	3,293,593
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value	2,225,819
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value	$ 2,225,819
Performance [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,008,747

Equity Based Compensation (RSU

Equity Based Compensation (RSU Activity) (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	1,124,000	535,000
Payments Related to Tax Withholding for Share-based Compensation	$ 0	$ 10,000,000	$ 46,000,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 7 months 6 days
Weighted Average Grant Date Fair Value of Restricted Stock Unit	$ 76,000,000	$ 57,000,000
Time Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	1,026,729	722,438
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	719,028
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	251,943
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease)	162,794
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value	$ 83.07	$ 91.42
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	72.56
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value	66.84
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value	$ 96.53
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	273,985	305,746
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	250,232
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	228,129
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease)	53,864
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value	$ 99.58	$ 83.75
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	98.49
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value	55.03
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value	$ 102.28
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	342,546	281,315
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	271,538
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	149,786
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease)	60,521
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value	$ 82.36	$ 91.04
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	65.69
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value	62.89
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value	$ 93.64
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 52,000,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years
Weighted Average Grant Date Fair Value of Restricted Stock Unit	$ 75.62	$ 109.63	94.19
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	$ 39,000,000	$ 33,000,000	$ 39,000,000

Other Income _ Expense (Details

Other Income / Expense (Details) - USD ($) $ in Millions		12 Months Ended
		Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Other Income and Expenses [Abstract]
Other Nonoperating Expense	[1]		$ 4	$ 18
Foreign Currency Transaction Gain (Loss), Unrealized	[2]	$ 8	(33)	(5)
Other Nonoperating Income (Expense)	[3]	(1)	9	20
Other (Income)/expense, net		7	(28)	(3)
Derivative, Gain (Loss) on Derivative, Net		0	$ 2	$ 17
Write-off of Deferred Debt Issuance Costs		4
Early Repayment of Senior Debt		11
Gain (Loss) on Extinguishment of Debt		$ 3
[1]Debt financing costs for the fiscal year ended June 30, 2022 consists of $4 million of financing charges related to a tranche of U.S. dollar-denominated term loans under its senior secured credit facilities. Debt financing costs for the fiscal year ended June 30, 2021 includes (a) a write-off of $4 million of previously capitalized financing charges related to the Company’s repayment of U.S. dollar-denominated term loans and the 2026 Notes in February 2021, (b) $3 million of financing charges related to the issuance of an earlier tranche of the Company's U.S dollar-denominated term loans, and (c) an $11 million premium on early redemption of the 2026 Notes.

Leases - Schedule of Operating

Leases - Schedule of Operating and Finance Leases Presented in the Balance Sheet (Details) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Assets and Liabilities, Lessee [Abstract]
Finance Lease, Right-of-Use Asset, after Accumulated Amortization	$ 274,000,000
Operating Lease, Right-of-Use Asset	59,000,000	$ 93,000,000
Finance Lease, Liability, Current	18,000,000
Operating Lease, Liability, Current	11,000,000
Finance Lease, Liability, Noncurrent	323,000,000
Operating Lease, Liability, Noncurrent	$ 55,000,000
Operating Lease, Liability, Statement of Financial Position [Extensible List]	Other Liabilities
Finance Lease, Liability, Statement of Financial Position [Extensible List]	Other Liabilities
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property, Plant and Equipment, Net
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property, Plant and Equipment, Net	Other Assets, Noncurrent

Leases - Cost (Details)

Leases - Cost (Details) $ in Millions	12 Months Ended
	Jun. 30, 2023 USD ($)
Lease, Cost [Abstract]
Finance Lease, Right-of-Use Asset, Amortization	$ 21
Finance Lease, Interest Expense	17
Finance Lease Expense	38
Variable Lease, Cost	10
Lease, Cost	83
Short-Term Lease Costs	$ 10
Finance Lease, Weighted Average Remaining Lease Term	17 years 4 months 24 days
Operating Lease, Weighted Average Remaining Lease Term	10 years 8 months 12 days
Finance Lease, Weighted Average Discount Rate, Percent	6.40%
Operating Lease, Weighted Average Discount Rate, Percent	4.30%
Operating Lease, Cost	$ 35

Leases - Schedule of Supplement

Leases - Schedule of Supplemental Cash Flow Information (Details) $ in Millions	12 Months Ended
	Jun. 30, 2023 USD ($)
Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]
Finance Lease, Principal Payments	$ 19
Finance Lease, Interest Payment on Liability	15
Operating Lease, Payments	16
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability	133
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	$ 1

Leases - Schedule of Maturities

Leases - Schedule of Maturities of Operating And Finance Lease Liabilities (Details) $ in Millions	Jun. 30, 2023 USD ($)
Leases [Abstract]
Finance Lease, Liability, Payments, Due Year One	$ 35
Finance Lease, Liability, Payments, Due Year Two	34
Finance Lease, Liability, Payments, Due Year Three	35
Finance Lease, Liability, Payments, Due Year Four	35
Finance Lease, Liability, Payments, Due Year Five	33
Finance Lease, Liability, Payments, Due after Year Five	380
Finance Lease, Liability, Payment, Due	552
Finance Lease, Liability, Undiscounted Excess Amount	211
Finance Lease, Liability	341
Lessee, Operating Lease, Liability, Payments, Due Year One	13
Lessee, Operating Lease, Liability, Payments, Due Year Two	10
Lessee, Operating Lease, Liability, Payments, Due Year Three	9
Lessee, Operating Lease, Liability, Payments, Due Year Four	9
Lessee, Operating Lease, Liability, Payments, Due Year Five	7
Lessee, Operating Lease, Liability, Payments, Due after Year Five	38
Lessee, Operating Lease, Liability, Payments, Due	86
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	20
Operating Lease, Liability	66
Total Lease Liability Payments Due Year One	48
Total Lease Liability Payments Due Year Two	44
Total Lease Liability Payments Due Year Three	44
Total Lease Liability Payments Due Year Four	44
Total Lease Liability Payments Due Year Five	40
Total Lease Liability Payments Due After Year Five	418
Total Lease Liability Payments Due	638
Total Lease Liability Undiscounted Excess Amount	231
Total Lease Liability	$ 407
Finance Lease, Weighted Average Remaining Lease Term	17 years 4 months 24 days

Segment Information - Net Reven

Segment Information - Net Revenue and Segment Ebitda (Detail) - USD ($)		12 Months Ended
		Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Segment Reporting, Revenue Reconciling Item [Line Items]
Net revenue		$ 4,263,000,000	$ 4,802,000,000	$ 3,998,000,000
Impairment charges and gain/(loss) on sale of assets		(98,000,000)	(31,000,000)	(9,000,000)
Equity compensation		(35,000,000)	(54,000,000)	(51,000,000)
Restructuring and other special items	[1]	(98,000,000)	(55,000,000)	(31,000,000)
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal		0	1,000,000	182,000,000
Other income (expense), net	[2]	7,000,000	(28,000,000)	(3,000,000)
Non-allocated corporate costs, net		(125,000,000)	(119,000,000)	(87,000,000)
Total unallocated costs		(559,000,000)	(286,000,000)	1,000,000
Softgel and Oral Technologies [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Segment EBITDA		548,000,000	589,000,000	498,000,000
Biologics [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Segment EBITDA		277,000,000	777,000,000	615,000,000
Biologics [Member] | Oxford
Segment Reporting, Revenue Reconciling Item [Line Items]
Asset impairments		54
Biologics [Member] | Swindon
Segment Reporting, Revenue Reconciling Item [Line Items]
Asset impairments		18
Total Catalent sub-total of Segment Reporting [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Segment EBITDA		$ 825,000,000	$ 1,366,000,000	$ 1,113,000,000
[1] Restructuring and other special items for the fiscal year ended June 30, 2021 include transaction and integration costs associated with the Anagni, Italy facility acquisition and the MaSTherCell Global, Inc., Skeletal, Delphi, and Acorda transactions, in addition to restructuring costs associated with the closure of the Company's Pharma and Consumer Health facility in Bolton, U.K. Other (income) expense, net for details of financing charges and foreign currency translation adjustments recorded within other (income) expense, net.

Segment Information - Reconcili

Segment Information - Reconciliation of Earnings/ (loss) from Continuing Operations to Ebitda (Detail) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Segment Reporting [Abstract]
Earnings/(loss) from continuing operations	$ (256,000,000)	$ 499,000,000	$ 585,000,000
Total unallocated costs	559,000,000	286,000,000	(1,000,000)
Depreciation and amortization	422,000,000	378,000,000	289,000,000
Interest expense, net	186,000,000	123,000,000	110,000,000
Income tax expense	$ (86,000,000)	$ 80,000,000	$ 130,000,000

Segment Information Total Asset

Segment Information Total Assets (Details) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	$ 10,777,000,000	$ 10,508,000,000
Biologics [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	5,746,000,000	5,770,000,000
PharmaConsumerHealth
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	4,867,000,000	4,356,000,000
Corporate and Eliminations [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	$ 164,000,000	$ 382,000,000

Segment Information Depreciatio

Segment Information Depreciation and Amortization (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Segment Reporting Information [Line Items]
Depreciation and Amortization	$ 422	$ 378	$ 289

Segment Information Capital Exp

Segment Information Capital Expenditures (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Segment Reporting Information [Line Items]
Payments and Accruals to Acquire Property, Plant. and Equipment	$ 594,000,000	$ 666,000,000	$ 686,000,000
Biologics [Member]
Segment Reporting Information [Line Items]
Payments and Accruals to Acquire Property, Plant. and Equipment	346,000,000	453,000,000	516,000,000
PharmaConsumerHealth
Segment Reporting Information [Line Items]
Payments and Accruals to Acquire Property, Plant. and Equipment	214,000,000	183,000,000	151,000,000
Corporate [Member]
Segment Reporting Information [Line Items]
Payments and Accruals to Acquire Property, Plant. and Equipment	$ 34,000,000	$ 30,000,000	$ 19,000,000

Segment Information - Assets an

Segment Information - Assets and Revenues (Detail) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Segment Reporting Information [Line Items]
Property, Plant and Equipment, Net	$ 3,682,000,000	$ 3,127,000,000
United States [Member]
Segment Reporting Information [Line Items]
Property, Plant and Equipment, Net	2,758,000,000	2,267,000,000
Europe
Segment Reporting Information [Line Items]
Property, Plant and Equipment, Net	765,000,000	747,000,000
International Other [Member]
Segment Reporting Information [Line Items]
Property, Plant and Equipment, Net	$ 159,000,000	$ 113,000,000

Supplemental Balance Sheet In_3

Supplemental Balance Sheet Information - Work-in-Process and Finished Goods Inventories Include Raw Materials, Labor and Overhead (Detail) - USD ($) $ in Millions	Jun. 30, 2023	Jun. 30, 2022
Balance Sheet Related Disclosures [Abstract]
Raw materials and supplies	$ 781	$ 651
Work-in-process	186	109
Total inventory, gross	967	760
Inventory cost adjustment	(190)	(58)
Inventories	$ 777	$ 702

Supplemental Balance Sheet In_4

Supplemental Balance Sheet Information - Prepaid and Other Assets (Detail) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Balance Sheet Related Disclosures [Abstract]
Prepaid Expense, Current	$ 53	$ 61
Contract with Customer, Asset, after Allowance for Credit Loss, Current	399	398
Spare Parts	24	22
Prepaid Taxes	77	27
Value Added Tax Receivable	38	48
Other current assets	42	70
Prepaid Expense and Other Assets, Current	633	626
Payments and Accruals to Acquire Property, Plant. and Equipment	$ 594	$ 666	$ 686

Supplemental Balance Sheet In_5

Supplemental Balance Sheet Information - Property and Equipment (Detail) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Balance Sheet Related Disclosures [Abstract]
Land, buildings, and improvements	$ 1,887,000,000	$ 1,687,000,000
Machinery and equipment	2,287,000,000	1,891,000,000
Furniture and fixtures	61,000,000	48,000,000
Construction in progress	1,043,000,000	848,000,000
Property and equipment, at cost	5,278,000,000	4,474,000,000
Accumulated depreciation	(1,596,000,000)	(1,347,000,000)
Property, plant, and equipment, net	$ 3,682,000,000	$ 3,127,000,000

Supplemental Balance Sheet In_6

Supplemental Balance Sheet Information - Other Assets Non Current (Detail) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Balance Sheet Related Disclosures [Abstract]
Operating Lease, Right-of-Use Asset	$ 59,000,000	$ 93,000,000
Loans and Leases Receivable, Gross	53,000,000	51,000,000
Cash Surrender Value of Life Insurance	41,000,000	35,000,000
Alternative Investment	36,000,000	33,000,000
Interest Rate Derivative Assets, at Fair Value	62,000,000	36,000,000
Other Assets, Miscellaneous, Noncurrent	42,000,000	21,000,000
Other Assets, Noncurrent	329,000,000	349,000,000
Deferred Income Tax, Right-of-Use Asset	59,000,000	93,000,000
Contract with Customer, Asset	18,000,000	43,000,000
Pension assets	$ 18,000,000	$ 37,000,000

Supplemental Balance Sheet In_7

Supplemental Balance Sheet Information - Other Accrued Liabilities (Detail) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Balance Sheet Related Disclosures [Abstract]
Deferred Income Tax Liabilities, Net	$ 160,000,000	$ 198,000,000
Interest Payable, Current	35,000,000	32,000,000
Deferred revenue and fees	167,000,000	211,000,000
Accrued income tax	44,000,000	50,000,000
Other accrued liabilities and expenses	134,000,000	140,000,000
Other accrued liabilities	570,000,000	646,000,000
Accrued Operating Lease, Liabilities	11,000,000	14,000,000
Restructuring accrual	19,000,000	1,000,000
Other Assets, Noncurrent	329,000,000	349,000,000
Non-current deferred tax asset	$ (55,000,000)	$ (49,000,000)

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2020	Oct. 31, 2023
Subsequent Event [Line Items]
Goodwill, Impairment Loss	$ 689	$ 210,000,000	$ 0	$ 0
Deferred Tax Assets, Valuation Allowance	$ 53,000,000	159,000,000	$ 149,000,000
Restructuring and Related Cost, Expected Cost					$ 25
PharmaConsumerHealth
Subsequent Event [Line Items]
Goodwill, Impairment Loss		$ 210,000,000